Novartis Confidential Page 2
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
Table of contents
Table of cont ents................................................................................................................. 2
List of tables ........................................................................................................................ 5
List of figures ...................................................................................................................... 6
List of abbreviations ............................................................................................................ 7
Glossary  of terms ............................................................................................................... 11
Amendment 3 (10 -Jun-
2020) ............................................................................................ 13
Amendment 2 .................................................................................................................... 16
Amendment 1 .................................................................................................................... 18
Protocol summary .............................................................................................................. 20
1Introduction ....................................................................................................................... 24
1.1 Background ............................................................................................................ 24
1.2 Purpose .................................................................................................................. 25
2Objectives and endpoints ................................ ................................ ................................ ...25
3Study  design ...................................................................................................................... 27
4Rationale ................................ ................................ ................................ ............................ 28
4.1 Rationale for stud y design ..................................................................................... 28
4.1.1 Rationale for choice of background therap y
......................................... 29
4.2
Rationale for dose/regimen and duration of treatment .......................................... 29
4.3 Rationale for choice of control drug s (comparator/placebo) or combination 
drugs ...................................................................................................................... 30
4.4 Purpose and timing of interim anal yses/design adaptations .................................. 30
4.4.1 Safety ..................................................................................................... 30
4.4.2 Efficacy ................................................................................................. 30
4.5 Risks and benefits .................................................................................................. 30
5Population ................................ ................................ ................................ .......................... 33
5.1 Inclusion criteria .................................................................................................... 33
5.2 Exclusion criteria ................................................................................................... 34
6Treatment ........................................................................................................................... 38
6.1 Study  treatment ...................................................................................................... 38
6.1.1 Investigational and control drugs .......................................................... 38
6.1.2 Additional study  treatments .................................................................. 39
6.1.3 Treatment arms/group ........................................................................... 39
6.1.4 Treatment duration ................................................................................ 40
6.2 Other treatment(s) .................................................................................................. 40
6.2.1 Concomitant therap y
............................................................................. 40
6.2.2
Prohibited medication ........................................................................... 45

Novartis Confidential Page 3
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
6.2.3 Rescue medication ................................................................................ 46
6.3 Subject numbering, treatment assignment, randomization .................................... 47
6.3.1 Subject numbering ................................................................................ 47
6.3.2 Treatment assignment, randomization .................................................. 47
6.4 Treatment blinding ................................................................................................. 47
6.5
Dose escalation and dose modification.................................................................. 48
6.5.1 Dose modifications ................................................................................ 48
6.5.2 Follow -up for toxicities ......................................................................... 49
6.6 Additional treatment guidance ............................................................................... 49
6.6.1 Treatment compliance ........................................................................... 49
6.6.2 Emergency  breaking of assigned treatment code .................................. 49
6.7 Preparation and dispensation ................................................................................. 50
6.7.1 Handling of study  treatment and additional treatment .......................... 50
6.7.2 Instruction for prescribing and taking study  treatment ......................... 51
7Informed consent procedures
............................................................................................ 52
8Visit schedu
le and assessments ......................................................................................... 53
8.1 Screening ............................................................................................................... 61
8.1.1 Information to be collected on screening failures
................................. 61
8.2
Subject demographics/other baseline characteristics............................................. 61
8.3 Efficacy .................................................................................................................. 62
8.3.1 Appropriateness of efficacy  assessments .............................................. 62
8.3.2 Spirometry ............................................................................................. 62
8.3.3
e-Diary ................................................................................................... 63
8.3.4 EXACT questionnaire ........................................................................... 63
8.3.5 St George's Respiratory  Questionnaire (SGRQ)
................................... 64
8.3.6 Patient global impression of severit y (PGI -S: general and specific) ....64
8.3.7 Cough And Sputum Assessment Questionnaire (CASA -Q)................. 64
65
65
66
66
8.4 Safety ..................................................................................................................... 67
8.4.1 Laboratory  evaluations .......................................................................... 68
8.4.2 Electrocardiogram (ECG) ..................................................................... 69
8.4.3 Pregnancy  and assessments of fertility ................................................. 69
8.5
Additional assessments.......................................................................................... 69
8.5.1 Pharmacokinetics .................................................................................. 69

Novartis Confidential Page 4
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
70
70
71
9Study  discontinuation and completion .............................................................................. 71
9.1 Discontinuation ...................................................................................................... 71
9.1.1 Discontinuation of investigational treatment ........................................ 71
9.1.2 Withdrawal of informed consent ........................................................... 73
9.1.3 Lost to follow -
up................................................................................... 73
9.1.4 Early study termination by the sponsor ................................................. 74
9.2 Study  completion and post -study  treatment .......................................................... 75
10Safety  monitoring and rep
orting ........................................................................................ 75
10.1 Definition of adverse events and reporting requirements ...................................... 75
10.1.1 Adverse events ...................................................................................... 75
10.1.2 Serious adverse events .......................................................................... 77
10.1.3 SAE reporting
........................................................................................ 78
10.1.4 Pregnancy  reporting .............................................................................. 79
10.1.5 Reporting of stud y treatment errors including misuse/abuse ................ 79
10.2 Additional Safety  Monitoring ................................................................................ 80
10.2.1 Liver safety  monitoring ......................................................................... 80
10.2.2 Renal safet y monitoring ........................................................................ 81
10.2.3 Data Monitoring Committee ................................................................. 81
11Data Collection and Database management ...................................................................... 81
11.1
Data collection....................................................................................................... 81
11.2 Database management and quality  control ................................ ............................ 81
11.3 Site monitoring ...................................................................................................... 82
12Data analy sis and statistical methods ................................................................................ 83
12.1 Analy sis sets .......................................................................................................... 83
12.2
Subject demographics and other baseline characteristics...................................... 83
12.3 Treatments ............................................................................................................. 83
12.4 Analy sis of the primary  endpoint(s) ...................................................................... 84
12.4.1 Definition of primary  endpoint(s) ......................................................... 84
12.4.2 Statistical model, hy pothesis, and method of anal ysis.......................... 85
12.4.3 Handling of missing values/censoring/discontinuations ....................... 87
12.4.4 Supportive analy ses............................................................................... 87
12.5 Analy sis of secondary  endpoints ........................................................................... 88
12.5.1 Efficacy  and/or Pharmacody namic endpoint(s) .................................... 88
12.5.2 Safety  endpoints .................................................................................... 90

Novartis Confidential Page 5
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
12.5.3 Pharmacokinetics .................................................................................. 91
92
92
92
12.7 Interim anal yses..................................................................................................... 93
12.7.1 Safety ..................................................................................................... 93
12.7.2 Efficacy ................................................................................................. 94
12.8
Sample size calculation.......................................................................................... 94
13Ethical considerations and administrative procedures ...................................................... 95
13.1 Regulatory
 and ethical compliance ........................................................................ 95
13.2 Responsibilities of the investigator and IRB/ IEC.................................................. 95
13.3 Publication of study  protocol and results ............................................................... 95
13.4 Quality  Control and Quality  Assurance ................................................................. 96
14Protocol adherence ............................................................................................................ 96
14.1 Protocol Amendments ........................................................................................... 96
15References ......................................................................................................................... 97
16Appendices ...................................................................................................................... 101
16.1 Appendix 1: Clinically  notable laboratory  values and vital signs ....................... 101
16.2 Appendix 2: L iver event and L aboratory  trigger Definitions and Follow
-up 
Requirements ....................................................................................................... 102
16.3 Appendix 3 Spirometry  guidance ........................................................................ 105
16.4 Appendix 4 CASA -
Q........................................................................................... 107
113
16.6
Appendix 6 EXACT questionnaire...................................................................... 114
117
16.8 Appendix 8 PGI ................................................................................................... 119
119
16.10 Appendix 10 CAT
................................................................................................ 121
16.11 Appendix 11 e -Diary  (for rescue medication) ..................................................... 123
16.12 Appendix 12: SGRQ ............................................................................................ 123
List of tables
Table 2
-1 Objectives and related endpoints .......................................................... 25
Table 6
-1 Investigational and control drug................................ ............................ 38
Table 6-2 Medications permitted under certain conditions................................ ...41
Table 6-3 Medications the exposure of which may  be modified by  co-
administration with QBW251 ............................................................... 42

Novartis Confidential Page 6
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
Table 6-4 Examples of contraceptives not recommended for sy stemic use 
(not acceptable as means of contraception as efficacy  may  be 
compromised by  QBW251 administration) .......................................... 44
Table 6
-5 Prohibited medication ........................................................................... 45
Table 6
-6 Prohibited COPD -related me dications .................................................. 46
Table 8
-1 Assessment Schedule ............................................................................ 54
Table 8
-2 Timed assessments for all visits ............................................................ 58
Table 8
-3 Timed assessments for Day  1 and Day  15 for subjects participating 
in the additional PK sampling sub -group (additional PK 
timepoints) ............................................................................................. 60
Table 8
-4 Assessments and Specifications............................................................ 67
Table 8
-5 Laboratory  paramet ers.......................................................................... 68
Table 10
-1 Guidance for capturing the study  treatment errors including 
misuse/abuse ......................................................................................... 79
Table 12
-1 Power and Precision.............................................................................. 94
Table 16-1 Liver Event and Laboratory  Trigger Definitions ................................ 102
Table 16-2 Follow Up Requirements for L iver Events and Laboratory  Triggers .102
List of figures
Figure 3 -1 Study  design .......................................................................................... 28
Figure 5 -
1 Illustration of inclusion criteria 6. and 7. .............................................. 34
Figure 12 -
1 Candidate Dose Response Curves ......................................................... 86

Novartis Confidential Page 7
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
List of abbreviations
AE adverse event
AIC Akaike information criterion
Alb Albumin
ALP alkaline phosphatase
ALT alanine aminotransferase
AST aspartate aminotransferase
ATS/ERS American Thoracic Society (ATS)/European Respiratory Society (ERS)
AUC Area under the plasma concentration -time curve
AUC 0-24h Area under the plasma concentration curve over 24 hours
b.i.d. twice a day
BCRP Breast Cancer Resistance Protein
BD bronchodilator
BMI Body Mass Index
BTPS body  temperature, pressure, saturated with water vapor
BUN blood urea nitrogen
CASA -Q Cough and sputum assessment questionnaire
CAT COPD assessment test
CF Cystic fibrosis
CFR Code of Federal Regulation
CFTR Cystic fibrosis transmembrane conductance regulator
Cmax Maximum concentration
Cmin Minimum concentration
CMO & PS Novartis Chief Medical Office and Patient Safety
COPD Chronic Obstructive Pulmonary Disease
COUI cough impact domain
COUS cough s ymptoms domain
COVID- 19 Corona Virus Disease 2019
CRA Clinical Research Associate
CRF Case Report/Record Form (paper or electronic)
CRO Commercial Research Organization
CT computer -assisted tomography
CTT Clinical Trial Team
CV coefficient of variation
CYP1A2 Cytochrome P450 1A2 enzy me
CYP2B6 Cytochrome P450 2B6 enzy me
CYP3A4 Cytochrome P450 3A4 enzy me
DAR Dose Administration Record
DDE Direct Data Entry
DMC Data Monitoring Committee

Novartis Confidential Page 8
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
DR Dose response
EC Ethics committee
ECG Electrocardiogram
eCRF Electronic Case Report Form
ED50 efficacious dose in 50% of subjects
EDC Electronic Data Capture
EDD expected date of deliver y
EMA European Medicines Agency
E-RS Evaluating Respiratory Symptoms in COPD
ER emergency  room
ERS European Respirator y Society
eSAE Electronic Serious Adverse Event
EU European Union
EXACT EXAcerbations of COPD Tool
FAS Full analy sis set
FDA Food and Drug Administration
FEV 1 Forced expiratory volume in one second
FVC Forced vital capacity
GCP Good Clinical Practice
GGT gamma -glutam yltransferase
GOLD The Global Initiative for Chronic Obstructive Lung Disease
h Hour
hCG Human chorionic gonadotropin
HCRU Health care resource utilization
IA Interim analysis
IB Investigator’s Brochure
ICF Informed consent form
ICH International Conference on Harmonis ation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use
ICS Inhaled CorticoSteroid
IEC Independent Ethics Committee
IN Investigator N otification
IND Investigational New Drug
IRB Institutional Review Board
IRT Interactive Response Technology
IUD intrauterine device
IUS intrauterine system
IVRS/I WRSinteractive voice response sy stem /interactive web- based response system
J2R jump-to-reference
LABA Long- Acting β2 -Agonist

Novartis Confidential Page 9
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
LAMA Long- Acting Muscarinic receptor Antagonist
LDH lactate dehydrogenase
LFT Liver function test
LLOQ Lower limit of quantification
MAR Missing at random
MCP -Mod Multiple comparison procedure -modelling
MedDRA Medical dictionary for regulatory activities
mg mi lligram (s)
mL mi lliliter(s)
mMRC modified Medical Research Council scale
MMRM Mixed -effect linear model for repeated measures
MRI magnetic resonance imaging
mRNA messenger Ribonucleic Acid
NDA New Drug Application
ng nanogram
NOAEL No Adverse Event Level
NYHA New York Heart Association
OAT3 Organic Anion Transporter 3
OATP1B1 Organic Anion Transporter 1B1
OATP1B3 Organic Anion Transporter 1B3
PD pharmacodynamic(s)
PGI-S Patient Global Impression of Severity
PK pharmacokinetic(s)
pMDI pressurized Metered Dose Inhaler
PRO patient -reported outcome
PSW premature subject withdrawal
PT/INR Prothrombin time international normalized ratio
QMS Quality Management System
QT QT interval (measure between Q wave and T wave in the heart's electrical cycle)
QTc corrected QT interval
QTcF QT interval with Fridericia's correction
RAS Randomized analysis set
RoW rest of world
SABA short -acting beta2 -receptor agonist
SAE serious adverse event
SAP Statistical analysis plan
SCS Systemic corticosteroids
SD standard deviation
SGRQ St George's Respirator y Questionnaire
SPUI sputum impact domain
SPUS sputum sy mptoms dom ain
SUSAR Suspected Unexpected Serious Adverse Reactions

Novartis Confidential Page 10
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
t.i.d 3times a day
TBL total bilirubin
Tmax time to reach maximum (peak) plasma concentration following drug administration
ug microgram
UGT UDP -glucuronosyltransferase
UGT1A1 Uridine Diphosphate -Glucuronosyltransferase 1A1
UGT2B7 Uridine Diphosphate -Glucuronosyltransferase 2B7
UK United Kingdom of Great Britain and Northern Ireland
ULN upper limit of normal
US United States of America
WHO World Health Organization

Novartis Confidential Page 11
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
Glossary  of terms
Additional 
treatmentMedicinal products that may be used during the clinical trial as described in the 
protocol, but not as an investigational medicinal product (e.g. any background 
therapy) .
Assessment A procedure used to generate data required by the study .
Cohort A specific group of subjects fulfilling certain criteria .
Control drug Any drug (an active drug or an inactive drug, such as a placebo) which is used 
as a comparator to the investigational drug being tested in the trial .
Dosage Dose of the study treatment given to the subject in a time unit (e.g. 100 mg 
once a day, 75 mg twice a day) .
Electronic Data 
Capture (EDC)Electronic Data Capture (EDC) is the electronic acquisition of clinical study 
data using data collection systems, such as Web-based applications, 
interactive voice response sy stems (IVRS) and clinical laborator y interfaces. 
EDC includes the use of Electronic Case Report Forms (eCRFs) which are 
used to capture data transcribed from paper source forms used at the point of 
care.
End of the study The end of the clinical study is defined as the last visit of the last subject or at a 
later point in time as defined in the protocol
Enrollment Point/time of subject entry into the study at which informed consent must be 
obtained (i.e. prior to starting any of the procedures described in the protocol)
Investigational 
drugThe study drug whose properties are being tested in the study; this definition is 
consistent with US CFR 21 Section 312.3 and Directive 2001/20/EC and is 
synony mous with “investigational new drug” or “test substance” .
Medication 
numberA unique identifier on the label of each study drug package in studies that 
dispense study drug using an IRT sy stem.
Other treatment Treatment that may be needed/allowed during the co nduct of the study (i.e. 
concomitant or rescue therapy)
Patient An individual with the condition of interest .
Period The subdivisions of the trial design (e.g.: Screening, Treatment, Follow -Up) 
which are described in the Protocol. Periods define the stud y phases and will 
be used in clinical trial database setup and eventually in analy sis.
Personal data Subject information collected by the investigator that is transferred to Novartis 
for the purpose of the clinical trial. This data includes subject identifier 
information, study information and biological samples.
Premature subject 
withdrawalPoint/time when the subject exits from the study prior to the planned 
completion of all study drug administration and assessments; at this time all 
study drug administration is discontinued and no further assessments are 
planned.
Randomization 
numberA unique identifier assigned to each randomized subject, corresponding to a 
specific treatment arm assignment .
Run-In Failure A subject who is screened but not ra ndomiz ed/treated after the run -in period 
(where run -in period requires adjustment to subject's intervention or other 
treatment) .
Screen Failure A subject who is screened but is not treated or randomized .
Source 
Data/DocumentSource data refers to the ini tial record, document or primary  location from 
where the data comes. The data source can be a database, a dataset, a 
spreadsheet or even hard -coded data, such as paper or eSource.
Stage A major subdivision of the study timeline; begins and ends with major study 
milestones such as enrollment, randomization, completion of treatment, etc.

Novartis Confidential Page 12
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
Start of the study The start of the study is defined as the signature of the informed consent by 
the first subject .
Study com pletion Point/time at which the subject came in for a final evaluation visit or when 
study drug was discontinued whichever is later.
Study drug 
discontinuationPoint/time when subject permanently stops taking study drug for any reason; 
may or m ay not also be the point/time of premature subject withd rawal.
Study 
drug/treatmentAny drug (or combination of drugs) administered to the subject as part of the 
required study procedures; includes investigational drug, active drug run -ins or 
background therapy.
Study treatment 
discontinuationWhen the subject permanently stops taking study treatment prior to the defined 
study treatment completion date .
Subject An individual who has consented to participate in this study. The term Subject 
may be used to describe either a healthy volunteer or a patient.
Subject number A num ber assigned to each subject who enrolls in the study. When com bined 
with the center number, a unique identifier is created for each subject in the 
study.
Treatment 
numberA unique identifier assigned in non- randomized studies to each dosed subject, 
correspond ing to a specific treatment arm.
Variable Information used in the data analy sis; derived directly or indirectly from data 
collected using specified assessments at specified timepoints.
Withdrawal of 
informed
consent (W oC)Withdrawal of consent from the study occurs only when a subject does not 
want to participate in the study any longer and does not allow any further 
collection of personal data .

Novartis Confidential Page 20
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
Protocol summary
Protocol number CQBW251B2201
Full Title A 24-week multi-center, double -blind, placebo controlled dose -range finding 
study to investigate the efficacy  and safety of oral QBW 251 in COPD patients 
on triple inhaled therapy (LABA /LAMA /ICS)
Brief title Dose -range finding efficacy and safety study for QBW 251 in COPD patients 
Sponsor and 
Clinical PhaseNovartis Pharma AG
Phase I ib
Investigation type Drug
Study type Interventional 
Purpose and 
rationaleThe purpose of this study is to support the dose selection for the future 
development program of QBW 251 by evaluating efficacy  and safety of different 
QBW251 doses in patients with Chronic Obstructive pulmonary disease 
(COPD )with chronic bronchitis and a histor y of exacerbations . QBW 251 
treatment will be added on top of a triple combination therapy of a long -active 
beta2 -agonist (LABA), a long-acting muscarinic receptor -antagonist (LAMA) 
and an inhaled corticosteroid ( ICS). 
The study  has a parallel design with QBW251 doses ranging from 25 to 
450mg administered twice daily (b.i.d.), which is expected to adequately 
describe the dose -response of QBW251. It is compared to placebo as a control 
in the absence of an approved COPD d rug in this class. 
The study will standardize the COPD background therapy to a 
LABA/LAMA/ICS triple combination to limit its confounding potential on the 
study outcomes. The choice of the medications reflects their global availability , 
the convenience of once daily dosing, and the recommendation of The Global 
Initiative for chronic Obstructive Lung Disease ( GOLD )strategy (GOLD 2018)
for use of triple inhaled therapy for exacerbating and symptomatic patients 
despite therapy with ICS/LABA or LABA/LAMA. This patient population closely 
mimi cs the patient population targeted by this study.
Primary 
Objective(s) The primary objective of this study  is to characterize the dose -response 
relationship of QBW 251 adm inistered orally over 12 weeks on lung function, 
compared to placebo, when added to inhaled triple combination therapy 
(LABA/LAMA/ICS). Trough forced expiratory volume in one second (FEV 1) will 
be assessed at Week 12 and evaluated as change from baseline after 12 
weeks of treatment.
Secondary 
ObjectivesObjective 1: To evaluate symptoms (overall COPD symptoms, cough and 
sputum) across various dose levels of QBW251 adm inistered orally over 24 
weeks, compared to placebo at W eeks 12 and 24.
Endpoints are
Change from baseline in the Evaluating Respirator y Symptoms in 
COPD (E -RS) weekly mean scores (total and subscale scores). 
Change from baseline in Patient Global Impression of Severity (PGI-
S) score.
Change from baseline in the Cough and Sputum Assessment 
Questionnaire (CASA -Q) domain scores -cough symptoms , cough 
impact, sputum sy mptoms, and sputum impact.

Novartis Confidential Page 21
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
Objective 2: To evaluate health -related quality of life across various dose levels 
of QBW251 adm inistered orally over 24 weeks, compared to placebo, at 
Weeks 12 and 24. The endpoint assessed is the change from baseline in St. 
George's Respiratory Questionnaire (SGRQ) total and domainscores at 
Weeks 12 and 24.
Objective 3: To e valuate lung function across various dose levels of QB W251 
administered orally over 24 weeks, compared to placebo, over 4, 8, 16, 20 and 
24 weeks. Trough FEV 1change from baseline after 4, 8, 16, 20 and 24 weeks 
of treatment, respectively , will be evaluated .
Objective 4: To evaluate safety and tolerability across various dose levels of 
QBW251, administered orally  over 24 weeks, compar ed to placebo , as assed 
by ECGs, laborator y tests (hematology and clinical chemistry , urinalysis) , vital 
signs, and adverse events (AEs) per treatment group.
Objective 5: To assess the pharmacokinet ics(PK) of QBW251 in COPD 
patients through measurement oftrough concentration and minimum 
concentration (Cmin) on all visits and around maximum concentration ( Cmax) on 
Days 1, 15 and 169. The area under the plasma concentration -time curve
(AUC )and C maxon Days 1 and 15 will be assessed in a sub-group of patien ts.
Study design This study uses a 6treatment arm, parallel -group, randomized, double -blind 
study design. One treatment arm (450 mg b.i.d.) has been discontinued. The 
study is placebo -controlled with a standardized COPD background treatment. 
The treatment period lasts 24 weeks, the total duration of study  participation 
for a patient is 31 weeks.
Population The study population will consist of approximately 956 male and female 
patients (≥40 years of age) with moderate to severe COPD (GOLD 2 and 3) 
and a smoking history of at least 10 pack years. It is expected that 
approximately  1500 patients will be screened globally to achieve the targeted 
number of randomized pa tients.
Key Inclusion 
criteriaMale and female COPD patients aged ≥ 40 years, who have signed 
an Informed Consent Form (ICF) prior to initiation of any study -
related procedure.
Current or ex -smokers who have a smoking history of at least 10 
pack y ears.
Patients who have been treated with a triple combination of 
LABA/LAMA/ICS for the las t 3 months prior to screening.
A COPD Assessment Test (CAT) score of at least 10 at Run -In 1
visit.
Patients with a post- bronchodilator FEV 1to forced vital capacity 
(FVC) ratio ( FEV 1/FVC) < 0.70 at Run -In 1visit.
Patients with airflow limitation indicated by
EITHER 
a post- bronchodilator FEV 1≥ 30%and FEV 1< 50%of the predicted 
normal at Run-In 1, who must have had at least 1 documented 
moderate or severe healthcare resource utilization (HCRU) 
exacerbation in the 12 months prior to study entry (screening), 
OR 
a post- bronchodilator FEV 1≥ 50%and < 80%of the predicted 
normal at Run -In 1, who mus t have had at least 2 documented 
moderate or at least 1 documented severe HCRU exacerbation(s) in 
the 12 months p rior to study entry (screening)

Novartis Confidential Page 22
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
Patients featuring chronic bronchitis, defined by the presence of 
cough and bronchial hypersecretion, that occu rs for at least 3
consecutive months in each of 2 consecutive years prior to study 
entry (screening), documented in patient histor y.
Key Exclusion 
criteriaPatients who have a history of long -QT sy ndrome, ora clinically 
significant ECG abnormality at Run-In 1 or Run -In 2, or whose
corrected QT interval ( QTc)measured at Run-In 1is prolonged. 
Patients who have clinically significant renal, cardiovascular, 
neurological, endocrine, immunological, ps ychiatric, gastrointestinal, 
or hematological abnormalitie s, which could interfere with the 
assessment of the efficacy  and safety of the study treatment, with a 
clinically significant laboratory abnormality at Run-In 1, or patients 
with T ype I diabetes or uncontrolled T ype II diabetes.
Patients who have had a COP D exacerbation that required treatment 
with antibiotics and/or oral corticosteroids and/or hospitalization, or a 
respirator y tract infection in the 4 weeks prior to screening, or 
between screening and Day 1. 
Patients with any documented history of asthma, or with an onset of 
chronic respiratory s ymptoms, including a COPD diagnosis, prior to 
age 40 years.
Patients with a body mass index (BMI) of more than 40 kg/m2.
Use of other investigational drugs (approved or unapproved) within 
30 days or 5 half -lives pr ior to screening, or until the expected 
pharmacodynamic (PD) effect has returned to baseline (e.g.
biologics), whichever is longer; or longer if required by local 
regulations.
Pregnant or nursing (lactating) women, and women of childbearing
potential not w illing to use acceptable effective methods of 
contraception during study  participation .
Study treatment Treatment arm 1: QB W251, 450 mg, b.i.d. (discontinued)
Treatment arm 2: QB W251, 300 mg, b.i.d.
Treatment arm 3: QB W251, 150 mg, b.i.d.
Treatment arm 4: QBW251, 75 m g, b.i.d.
Treatment arm 5: QB W251, 25 m g, b.i.d.
Treatment arm 6: Placebo matching QB W251, b.i.d.
All patients are receiving standardized background COPD medication 
consisting of fluticasone furoate, umeclinidium and vilanterol.
Efficacy 
asse ssmentsSpirometric assessments (forced spirometry )
Electronic diar y/EXACT questionnaire
St. George’s Respiratory Questionnaire (SGRQ)
Patient global impression of severity questionnaires
Cough and Sputum Assessment Questionnaire (CASA -Q)
Pharmacokinetic 
assessmentsPharmacokinetic blood sampling

Novartis Confidential Page 24
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
1 Introduction
1.1 Background
Chronic obstructive pulmonary  disease (COPD) is characterized by persistent respiratory 
symptoms (dyspnea, cough, sputum production) and airflow limitation (diagnosed using 
spirometry ) that is due to airway  and/or alveolar abnormalities usually  caused by significant 
exposure to noxious particles/gases, in particular cigarette smoke. Chronic airflow limitation is 
cause d by a mixture of small airways disease (obstructive bronchiolitis) and parench ymal 
destruction (emph ysema).
COPD is a criticall y important disease, with a prevalence of 10% to 15% in Europe 
(Blanco et
al2018), approxi mately  10% in South East Asia and approximately  15% in the 
Americas (Adeloy eet
al2015). COPD affects over 15 million people in the United States of 
America (US)alone (National Cen
terforHealth etal2017), and is the third leading cause of 
death worldwide ( World Health Organization 2018 ). COPD is associated with episodic periods 
of symptom deterioration termed exacerbations. Exacerbations are a mongst the most common 
causes of medical admission to hospital and are also important events in the natural history  of 
COPD that drive lung function decline (Donaldson et
al2002), increased risk of cardiovascular 
event s (Donaldson et
al2010) and are responsible for much of the morbidity  and mortality 
associated with this highly  prevalent condition ( Soler -
Cataluña et al 2005 ).
COPD is also associa ted with significant healthcare expenditures with total economic costs in 
the US estimated at $49.9 billion in 2010, and total direct costs of medical care estimated at 
$29.5 billion annually . Direct costs associated with hospitalizations for COPD exacerba tions in 
the US exceed $20 billion annually  (Guarascio et al 2013). In the European Union, the annual 
costs of healthcare and lost productivity  due to COPD are 
estimated at €48.4 billion (ERS 2013).
Chronic bronchitis, due to mucous hypersecretion and mucociliary  dysfunction characterized 
by chronic cough and sputum, is a key  phenot ype amongst COPD patients. Bronchitic patients 
have higher exacerbation frequency  (Seemungal et
al1998) and are more likely  to be 
hospitalized (Vestbo et
al1996, Kim et al 2011 ). However ,effective treatment options are 
extremely  limited in this group. Current standard of care in the management of COPD consists 
of bronchodilators ±inhaled corticosteroids with triple inhaled therap y (long -acting β2 -agonist 
+ long-acting muscarinic receptor antagonist + inhaled corticosteroid =LABA+LAMA+I CS) 
indicated in patients experiencing exacerbations with dual combination treatments 
(LAMA+LABA, LABA+I CS). The guidelines also consider macrolide antibiotics and 
roflumilast as additional add-on therapy  to triple therapy  in specific sub-group s of patients: in 
fact 30% to 40% of patients receiving triple inhaled therap y continue to have moderate or severe 
(hospitalized) exacerbations (Vestbo et
al2017, Mullerova et al2017). However, long-term 
macrolide antibiotics are complicated by microbial resistance (Pomares et
al2018) and 
roflumilast, a non-bronchodilator (PDE4 inhibitor) ,has modest efficac y and poor tolerability 
(Chong et al 2017 ). Mucoly tics have shown small and inconsistent benefits on exacerbation 
reduction and the efficacy  of mucol ytics on top of maximal inhaled treatment has yet to be 
clearl y establ ished (Wedzicha et al 2017). Thus despite currentl y available treatments almost 
70% of patients remain 
significantl y limited by breathlessness (modified Medical Research 
Council scale (mMRC )≥ 2) and 40% experience ≥ 2 moderate or ≥ 1 severe exacerbation per 
year (Mullerova et al 2017), therefore additional novel therapies are urgently  needed.

Novartis Confidential Page 25
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
Research indicates that cigarette smoking induces an acquired state of cystic fibrosis 
trans membrane conductance regulator (CFTR) dysfunction in the respiratory  tract 
(Cantin et al 2006), even in the absence of CFTR mutations, and may contribute to the 
pathogenesis of COPD. CFTR dysfunction due to smoke exposu re adversel y affects 
mucociliary  transport and is strongly  associated with symptoms of chronic bronchitis 
(Sloane et
al2012). Cigarette smokers and COPD patients exhibit reduced CFTR function by 
nasal potential differe nce measurements, accompanied by reduced CFTR mRNA levels 
(Cantin et al 2006, Sloane et al 2012, Dransfield etal2013). Furthermore, current andformer 
smokers with COPD have elevated sweat chloride levels compared with normal control subjects, 
indicating reduced CFTR activity  (Raju et
al2013).
Modulation of CFTR function should improve airwa y hydration, decre
asing mucus viscosit y 
and so enhancing mucociliary  clearance. CFTR also regulates bicarbonate secretion, whose 
effect on airway  surface liquid pH is important in the fight against pathogens 
(Pezzulo et al 2012). This mechanism would support a reduction of the airway 
inflammation/infections and obstruction leading to clinical benefits such as improvement of 
respiratory  function, symptoms of COPD, and a decrease in the rates of exacerbations and 
respiratory  tract infection s.
CFTR potentiators increase the activity  of the CFTR channel that is present in the cell 
membrane of the lungs epithelium: this can include wild type CFTR. QBW251 is a novel 
potentiator of the CFTR channel that is safe and well -tolerat ed. In study  CQBW25 1X2201, a 
28-day randomized, placebo -controlled trial, QBW251 in GOLD 2-3COPD patients with 
chronic bronchitis and with various background inhaled therapies demonstrated improvement 
in lung function (FEV 1) and sweat chloride over placebo, in addition to reducing systemic 
inflammation (measured by fibrinogen). Furthermore, exploratory  sputum analy ses have 
suggested a trend for decreased bacterial colonization with QBW251.
Therefore, QBW251 will be a first -in-class oral CFTR potentiator, with the capacit y toreduce 
COPD exacerbations and improve symptoms, quality  of life and lung function when added to 
inhaled therapies.
1.2 Purpose
The purpose of this Phase 2b study  is to support the dose selection for future studies by 
evaluating efficacy  and safet y of different QBW251 doses in COPD patients with chronic 
bronchitis and a history of exacerbations, compared to placebo, when added to a triple 
combination therap y of LABA/LAMA/ ICS. Lung function improvement will be the primar y 
endpoint: trough FEV 1change from baseli ne after 12 weeks of treatment.
The study  will also provide information on longitudinal spirometry  assessments over 24 weeks, 
patient reported outcome (PRO) tools and safet y.
2 Objectives and endpoints
Table 2-1 Objectives and related endpoints
Objective(s) Endpoint(s)
Primary objective(s) Endpoint(s) for primary objective(s)

Novartis Confidential Page 29
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
4.1.1 Rationale for choice of background therapy
The study  will standardize the COPD backgroun d therapy  to limit its confounding potential on 
the study  outcomes. The selected standard background therap y will consist ofa triple inhaled 
combination (LABA/LAMA/I CS): either a fixed combination of fluticasone furoate, vilanterol 
and umeclidinium, or, where not accessible, a free combination of fluticasone furoate/vilanterol 
and umeclidinium. The choice of these medications reflects their global availability  and the 
convenience of once daily  dosing. GOLD strategy  (GOL D 2018) suggests the use of triple 
inhaled therapy  for exacerbating and sy mptomatic patients despite therapy  with ICS/LABA or 
LABA/LAMA. This patient population closel y mimics the patient population targeted by this 
study .
4.2 Rationale for dose/regimen and du ration of treatment
QBW251 is a small molecule intended for oral administration. Half -life of QBW251 follo
wing 
single dose ranges from 10 to16 hours. The twice -daily  dosing regimen was chosen based on 
the half -life and the intent to have a sustained effect on the ion channel. Additionally  a twice -
daily  regimen would provide a reduced C max/trough fluctuation compared to once daily dosing. 
A twice -daily regimen was also tested in the proof of concept study  (CQBW251X2201) and 
was shown to be effective in COPD patients at 300 mg b.i.d.
The study  covers a dose range from 25 to 450 mg b.i.d., which is expected to adequately 
describe the dose-response of QBW251. While the COPD proof of concept study 
CQBW251X2201 has provided evidence of efficacy  with a 300 mg b.i.d. regimen, there is no 
indication that this regimen may  have reached the plateau of the dose-response . Therefore, the 
450 mg b.i.d. was also proposed. The 450 mg b.i.d. regimen was well tolerated in an earlier 
study  in cy stic fibrosis (CF) patients (CQBW25 1X2101). The respective treatment arm in this 
study  has been stopped and patients 
on the 450 mg b.i.d. regimen have been prematurel y 
discontinued from treatment after the Data Monitoring Committee (DMC) had found that the 
criterion for the pre-defined pharmacokinetic -based cohort stopping rule (Section 9.1.4.1) had 
been fulfilled. The DMC confirmed that the regimen was also well tolerated in this patient 
population and the stop was not based on adverse reactions to the 450mg b.i.d. regimen. The 
lowest dose (25 mg b.i.d.) is intended to capture the location of the increasing part of the dose -
response curve (e.g.around the 
efficacious dose in 50% of subjects (ED50 )) to ensure that the 
efficacy  dose-response curve and the therapeutic margin of QBW251 are well characterized. 
Due to the limited available data, ED50 as low as 25 mg b.i.d. cannot be excluded, hence the 
selection of this dose. The 75 and 150 mg b.i.d. regimens have been selected to achieve uniform 
coverage of the exposure range between the lowest dose and the higher doses described above 
to enable a sufficientl y granular description of the dose
-response curve.
Twelve weeks of treatment are sufficient to detect a spirometric signal ( FEV 1) and are aligned 
with a symptomatic benefit reflective of the target profile of QBW251. A positive signal across 
these endpoints at this timepoint would enable an early decision making for a transition into 
confirmatory  Phase 3.
The 24-week treatment enables a longer longitudinal assessment, which is more aligned with 
the intended chronic use of QBW251. The proposed exposure will also increase the robustness 
of the safet y and tolerability  assessment and may provide exploratory  insights relative to the 
effect.

Novartis Confidential Page 30
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
4.3 Rationale for choice of control drugs (comparator/placebo) or 
combination drugs
There is currentl y no approved CTFR potentiator for treatment of COPD on top of triple inhaled 
therap y of LABA/LAMA/I CS that could serve as a comparator. Therefore, QBW251 is tested 
against placebo on top of triple inhaled therapy , which is also in accordance with the robust 
method for the evaluation of an investigational agent, to standards meeting both regulatory  
requirements and accepted scientific principles. This includes optimizing the study  design for 
high levels of confidence in the rigor and validity of the resulting data, and minimizing the risk 
of inconclusive results.
4.4 Purpose and timing of interim analy ses/design adaptations
4.4.1 Safety
In addition to monitoring safet y data, an independent external safety  data monitoring committee 
(DMC) will evaluate the results of pre -specified interim PK to ensure that patients' exposures 
are generall y consistent with an exposure threshold, see Section 9.1.4.1 and Section 12.7.1.
Based on their review, the DMC can make recommendations regardi
ng the conduct of the trial. 
Recommendations from the DMC could trigger alteration of the curren t protocol, such as 
termination of a treatment arm. The communication flow process of the outcome of their 
reviews and any other recommendations by the DMC Chairman, on behalf of the members, will 
be outlined in the DMC charter. The planned interim analy ses will be performed when the 
predefined amount of data are available; details are included in the DMC charter.
4.4.2 Efficacy
Up to 2 interim analy ses (IAs) may  be conducted on efficacy  data. The purpose of the IA(s) is 
to have an early  assessment of the efficac y data for planning future studies in the QBW251B 
program. The first IA will be triggered when approximately  the first 645to 680randomized 
patients have either discontinued or completed 12 weeks of treatment. If the first IA does not 
lead to a clear decision for the planning of the QBW251B program, a second IA may be 
performed when all randomized patients have either discontinued or completed 12 weeks of 
treatment. The efficacy  IA results will not trigger any  design adaptations.
4.5 Risks and benefits
The risks to subjects in this trial will be minimized by compliance with all of the eligibility 
criteria and by close clinical monitoring which will include PK monitoring as well.
The inclusion and exclusion criteria are selected to enroll patients with COPD thatare most 
likely  to benefit from QBW251 while participating in the study : symptomatic patients at higher 
risk of exacerbations defined by the CAT score, presence of chronic bronchitis, and with a 
history  of exacerbations in the 12 month prior to study  entry. The study  requires all patients to 
be on a triple combination (LABA/LAMA/ICS). The standardization of the concomitant COPD 
treatment aims at limiting the variability  from this potential confounding source and ensures 
treatment of all patients, including those randomized to placebo. Accordingly , patients remain 
on the triple COPD background therap y throughout the study . 

Novartis Confidential Page 31
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
Potential risks of QBW251 are the common adverse events of QBW251 as noted in previous 
studies, comprising ofgastrointestinal events (n ausea, diarrhea, vomiting) and nervous system 
disorders (headache, fatigue and dizziness). There is also the possibility  of hypersensitivity 
reactions against QBW251.
The most common adverse effects associated with the standardized triple COPD background 
therap y are headache, back pain, dysgeusia, diarrhea, cough, orophary ngeal pain, 
nasophary ngitis, upper respiratory  tract infection, arthralgia, gastroenteritis, and oral 
candidiasis (approved labels for Trelegy  Ellipta, Breo Ellipta (EU name Relvar Ellipta )and 
Incruse Ellipta). Recent data also suggests a potential increase of the risk of pneumonia 
(including fatal cases) related to the use of the inhaled corticosteroid (update to approved label 
for Trelegy  Ellipta in September 2017).
Clinical monitoring includes the use of an electronic diary  with the EXACT questionnaire to 
enable daily symptoms assessment, as well as safet y assessments during visit days at the 
investigational site. These include a careful assessment of adverse events, as well as triplicat e
ECGs, hematologic and clinical chemistry  laboratory  assessments, urinaly sis and vital signs 
measurements. As a formal thorough QT assessment of QBW251 has not been completed, 
triplicate ECGs pre -and post -dose (at thetime to reach maximum (peak) plasma concentration 
following drug administration (Tmax)) will be performed at Day  1, at Day 1 5 (when all patients 
have reached steady  state concentration of the investigational drug), and at Day 169 (end of 
treatment). These assessments will be complemented by the corresponding PK sampling 
(trough and C max). The PK sampling is also part of a more granular PK monitoring (detailed in 
schedule of assessment Table 8-1), which has been put in place to ensure that patient exposures 
are in general consistent with a threshold (
area under the plasma concentration curve over 24 
hours (AUC 0-24h) = 91 700 ng×h/mL ) that was established based on animal (monkey ) data. As 
this threshold represents an average of the exposures observed in those animals after 39 weeks 
of treatment with QBW251, this limit is not absolute and few patients are expected to exceed it. 
In prior QBW251 studies, patients with exposures above this threshold reported either no 
adverse events or mild to moderate ones.
In addition t o the sampling described above, the PK monitoring plan will generate C mindata at 
all visits and additional PK samples are requested to be taken in case of treatment -
emergent 
serious adverse events. Study  drug discontinuation and cohort stopping rules related to exposure 
have been introduced into the protocol as well (see Section 9.1.4.1)
Finally  a sub
-group of approximately  48 patients will undergo serial PK assessments to further 
characterize the PK profile of QBW251 bef ore transitioning into the confirmatory  Phase 3.
Investigators and patients will be instructed how to react to worsening of COPD symptoms and 
exacerbations. For the worsening of COPD symptoms, a short -acting beta -2 agonist (SABA) is 
provided as rescue medi cation. With respect to the treatment of exacerbations, a suggested 
therap y consists of 5days of oral prednisolone (or equivalent) 40 mg/day  and/or an oral 7 day 
course of amoxicillin 500 mg three times per day ( t.i.d.)(alternativel y amoxicillin clavulan ate 
625 mg t.i.d. or clarithromy cin 500 mg b.i.d.), though investigators arefree to treat COPD 
exacerbations according to the medical needs of the patients. The diary  will also trigger alerts 
to both patients and investigators when an algorithm detects a deterioration of symptoms 
compatible with an exacerbation. The investigator will provide the patient with written 
instructions to contact them if sy mptoms of COPD worsen.

Novartis Confidential Page 32
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
Procedural risks in this clinical trial are local reactions to venipuncture, includin g pain, 
hematomas, fainting, swelling, infections, and erythema. Forced spirometry  testing on visit days 
may furthermore induce cough, d yspnea and dizziness.
Women of childbearing potential must be informed that taking the study  treatment may involve 
unknown risks to the fetus if pregnancy  were to occur during the study , and agree that in order 
to participate in the study they must adhere to the contraception requirements outlined in the 
exclusion criteria for the duration of their study  participation. If withdrawing from the study 
prematurel y
, contraception as stipulated should be continued for at least 7 daysfollowing the 
last administration of investigational medicinal product . If there is an y question that the subject 
will not reliably  comply, sheshoul d not be entered or continue in the study . Based on a 
reproductive toxicity  study, women of childbearing potential are allowed to enter the study  as 
long as they are using anacceptable effective method of contraception (see also exclusion 
criteria). This group of patients is relevant for the targeted disease and their inclusion is aligned 
with the International Conference on Harmonis ation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH)M3 (R2) guidance. However, in a 
hormonal contraception study , it was demonstrated that QBW251 enhances cytochrome 
pathway s that lead to accelerated degradation of hormone levels; systemic hormones are 
therefore not approved as an acceptable effective method of contraception in this study .
Reflecting the currentl y limited characterization of QBW251 potential for clinical drug-drug 
interactions, the protocol uses cautionary  language for drugs that may  potentially  interact with 
QBW251 based on available in vitro data. These drugs are sensitive substrates of CYP1A2, 
CYP2B6, CYP3A4, OAT3, BCRP, OATP1B1, OATP1B3, UGT1A1, and UGT2B7 (see List 
of abbreviations for full protein names) . These drugs are not prohibited but their substitution 
with alternati ve agents is advised: when not possible closer monitoring is recommended.
Additionally  use of sensitive substrates of CYP1A2 with a narrow therapeutic range is 
prohibited. Due to the involvement of multiple metabolic pathways in QBW251 metabolism, it 
is anticipated that the use of QBW251 with concomitant drugs will likely have no significant 
clinical impact on QBW251 exposure. However, as Uridine Diphosphate -
Glucuronos yltransferase (UGT )mediated glucuronidation is likely  a  significant elimination 
pathway , use of certain UGT inhibitors is prohibited.
QBW251 may also impact the systemic 
exposure of the individual components of inhaled triple 
therap y LABA/LAMA/ICS, whose most common adverse effects have been described above. 
However, efficacy  of the triple therapy is not expected to be impacted due to the delivery 
directly  to the lungs. Please refer to the respective labels of LABA/LAMA/I CS for additional 
information on drug interactions. Any concomitant medications should be noted in the 
electronic Case Report Form (eCRF) . As additional information becomes available when 
clinical drug interaction studies are conducted during the QBW251 development program, this 
information will be further updated and reflected in the QBW251 I nvestigator's Brochure (IB).
With respect to clinical benefits, a proof of concept study  showed an improvement of pulmonary 
function (FEV 1) and provided additional observations that could be associated with a restoration 
of the mucociliary  clearance (decrease in systemic fibrinogen and reduc tion of the bacterial load 
of selected pathogens). Nevertheless, the exploratory  nature of the latter observations will 
require further assessment to confirm them.

Novartis Confidential Page 33
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
Finally , an independent Data Monitoring Committee will oversee the developing clinical 
datab ase and ensure the well-being of the patients throughout the stud y.
5 Population
The study  population will consist of approximately 956male and female patients (≥ 40 years 
of age) with moderate to severe COPD (GOLD 2 and 3) and a smoking history  of at least 10 
pack years. Assuming a screen -failure rate of40%, it is expected that approximately  1500 
patients will be screened globally to achieve the targeted number of randomized patients. 
5.1 Inclusion criteria
Subjects eligible for inclusion in this study  must meet allof the following criteria:
All patients in the study
The following criteria apply  to all patients in the QBW251B2201 study .
1.Patients who have signed an Informed Consent Form prior to initiation of any study -
related procedure.
2.Male and female adults aged ≥ 40 years.
3.Patients with stable COPD according to the current GOLD strategy  (GOLD 2018) at 
Screening visit .
4.Patients who have been treated with a triple combination of L ABA/LAMA/I CS for the l ast 
3 months prior to screening . Fixed or free combinations are acceptable, but will be 
exchanged for standard combinations at Run -In 1.
At the Run
-In 1 visit , the background treatment will be switched to a fixed combi nation of 
fluticasone furoate, vilanterol and umeclidinium, or, where not accessible, to a free 
combination of fluticasone furoate/vilanterol and umeclidinium.
5. A COPD Assessment Test (CAT) score of at least 10 at Run- In 1.
6.Patients with a post -bronchodilat or FEV 1/FVC < 0.70 at Run -In 1.
7.Patients with airflow limitation indicated by
EITHER 
a post -bronchodilator FEV 1≥ 30% and FEV 1< 50% of the predicted normal at Run-In 1, 
who must have had at least 1 documented moderate or severe healthcare resource 
util
ization (HCRU) exacerbation in the 12 months prior to study  entry  (screening), 
OR 
a post -bronchodilator FEV 1≥ 50% and < 80% of the predicted normal at Run -In 1, who 
must have had at least 2 documented moderate or at least 1 documented severe HCRU 
exacer bation(s) in the 12 months prior to study  entry  (screening).
Notes:
Post-
bronchodilator refers to 3 0 to 60 min after inhalation of 400 µg salbutamol/360 
µg albuterol (or equivalent dose).
HCRU exacerbations are defined as moderate if leading to treatment with sy stemic 
glucocorticosteroids and/or antibiotics, and as severe if leading to hospital admission 
or emergency  room (ER) visit lasting > 24 h in addition to treatment with sy stemic 
glucocorticosteroids and/or antibiotics.

Novartis Confidential Page 35
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
All patients in the study
The following criteria apply  to all patient s in the QBW251B2201 study .
1.Patients with a history  of long -QT s yndrome or whose QTc measured at Run -In 1 is 
prolonged (QTc > 450 ms in males, > 460 ms in females; Fridericia method), confirmed 
by the central overreader.
2.Patients who have a clinically  significant ECG abnormality  at the start of Run -In 1 or at 
the end of run -in (Run
-In 2).
Note: Clinically  significant abnormalities may  include but are not limited to the following: 
left bundle branch block, Wolff -Parkinson- White sy ndrome, clinicall y significa nt 
arrhythmias ( e.g.atrial fibrillation, ventricular tachy cardia).
Note: These patients must not be re
-screened.
3.Patients who have a clinically  significant laboratory  abnormalit y at Run -In 1. For 
additional guidance on hepatic parameters see exclusion criterion #5.
4.Patients who have clinically  significant renal, cardiovascular (such as but not limited to 
unstable ischemic heart disease, New York Heart Association ( NYHA )Class III/ IV left 
ventricular failure, m yocardial infarction), neurological, endocrine, immunological, 
psychiatric, gastrointestinal, or hematological abnormalities, which could interfere with 
the assessment of the efficacy  and safety  of the study  treatment, or patients with Ty pe I 
diabetes or uncontrolled Ty pe II diabetes.
Note: Clinically  significant is defined as an y disease that, in the opinion of the 
investigator, would put the safet y of the patient at risk through participating, or which 
would affect the efficacy  or safet y anal ysis if the disease/condition exacerbated during the 
study , or would compromise patient compliance or preclude completion of the study .
5.Patients with a history  or current treatment for hepatic disease including but not limited to 
acute or chronic hepatitis, cirrhosis or hepatic failure or prothrombin time international 
normalized r atio ( PT/INR) of more than 1.5x upper limit of normal range ( ULN )at 
Run-In1.A history  of resolved hepatitis A is not exclusionary .
Patients excluded for the PT/INR of more than 1.5x ULN can be re -screened when the 
values have returned t o normal.
6.
Patients contraindicated for treatment with, or having a history  of 
reactions /hypersensitivity  to any  of the following inhaled drugs, drugs of a similar class or 
any component thereof:
Muscarinic antagonist agents,
Long -and short -acting β2 -agoni sts,
Sympathomimetic amines,
Inhaled corticosteroids
Inhaled lactose or an y of the other excipients of the trial medication, including an y 
background or rescue medication.
7.Patients with a history  of malignancy  of an y organ sy stem, treated or untreated, within the 
past 5 y ears whether or not there is evidence of local recurrence or metastases, with the 
exception of localized basal cell carcinoma of the skin. Patients with a history of cancer 
and 5 y ears or more disease free survival time may  be included i n the study  by agreement 
with Novartis Medical Monitor on a case -by-case basis.

Novartis Confidential Page 36
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
8.Patients who have not achieved an acceptable spirometry  result at Run- In 1 in accordance 
with American Thoracic Society  (ATS)/European Respiratory  Societ y (ERS) criteria for 
acceptability  and repeatability  (refer to Section 16.3 Spirometry  Guidance).
Note: one re -test may  be performed in patients that do not meet the ATS/ERS criteria. 
Patients who have failed the test and re -test at Run -In 1may be re -screened maximally  
twice.
9.Patients who have had a COPD exacerbation that required treatment with antibiotics 
and/or oral corticosteroids and/or hospitalization in the 4 weeks prior to screening. 
Patients can be re
-screened after a minimum of 4 weeks after the resolution of the COPD 
exacerbation.
10.Patients who develop a COPD exacerbation that required treatment with antibiotics and/or 
oral corticosteroids and/or hospitalization between screening and prior to treatment Day  1 
will not be eligible, but wil l be permitted to be re -screened after a minimum of 4 weeks 
after the resolution of the COPD exacerbation.
11.Patients who have had a respiratory  tract infection within 4 weeks prior to screening. 
Patients can be re- screened after a minimum of 4 weeks after r esolution of the respiratory  
tract infection.
12.Patients who develop a respiratory  tract infection between screening and prior to treatment 
Day 1 will not be eligible, but will be permitted to be re-screened 4 weeks after the 
resolution of the respiratory  tract infection.
13.Patients requiring long term ox ygen therap y prescribed for > 12 hours per day .
14.Patients with any  documented history  of asthma.
Note: Documented history refers to patient history recorded at screening, documented in 
source notes, pharmacy  records, hospital records, chart records, referral records, or an y 
other medical records of the patient.
15.Patients with an onset of chronic respiratory  symptoms, including a COPD diagnosis, 
prior to age 40 years.
16.Patients with concomitant pulmonary  disease (e .g. clinically  significant bronchiectasis, 
lung fibrosis, sarcoidosis, interstitial lung disease, pulmonary  hypertension, α -1 anti -
trypsin deficiency ) or patients known to have CFTR mutation(s).
17.Patients with suspected active pulmonary  tuberculosis or curr ently being treat edfor active 
pulmonary  tuberculosis.
Note: Patients with a history  of pulmonary  tuberculosis can be enrolled if they  meet the 
following requirements: history  of appropriate drug treatment followed by negative 
imaging results within 12 mon ths prior to screening suggesting low probability  of 
recurrent active tuberculosis.
18.Patients with pulmonary  lobectomy , lung volume reduction surgery , bronchoscopic lung 
volume reductions, or lung transplantation.
19.Patients participating in or planning to participate in the active phase of a supervised 
pulmonary  rehabilitation program during the trial. Participation in a maintenance program 
is permitted. Note: the supervised pulmonary  rehabilitation program as a maintenance 
program has to be ongoing for at least 3 months at the time of enrollment.
20.Patients with a body  mass index (BMI) of more than 40 kg/m2.
21.Patients receiving an y medications in the classes listed in Table 6-5.

Novartis Confidential Page 37
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
22.Patients receiving an y COPD related medications in th e classes specified in Table 6-6, 
unless they  
undergo the required washout period prior to screening and follow the 
adjustment to treatment program.
23. Patients receiving medications in the classes listed in Table 6-2should be excluded unless 
the medication has been stabilized for the specified period and the stated conditions have 
been met.
24.Use of other investigational drugs (approved or unapproved) within 30 days or 5 half -lives 
prior to screening, o r until the expected pharmacody namic effect has returned to baseline 
(e.g.biologics), whichever is longer; or longer if required b y local regulations.
25.Patients unable or unwilling to compl y with study -related visits or procedures, including 
use of an elec tronic patient diary  and EXACT pro diary .
26.Patients unable to use a dry  powder inhaler device, metered dose inhaler, or a pressurized 
MDI  (rescue medication) or comply  with the study  drug regimen.
27.Pregnant or nursing (lactating) women, where pregnancy  was d efined as the state of a 
female after conception and until the termination of gestation, confirmed b y a positive 
human chorionic gonadotropin (hCG) laboratory
 test.
28.Women of childbearing potential, defined as all women physiologicall y capable of 
becoming p regnant, unless they  are using acceptable effective methods of contraception 
during study  participation . Acceptable effective contraception methods include:
Total abstinence (when this is in line with the preferred and usual lifest yle of the 
subject). 
Periodic abstinence ( e.g.calendar, ovulation, sy mptothermal, post- ovulation 
methods) and withdrawal are not acceptable methods of contraception.
Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y) total h ysterectom y or bilateral tubal ligation at least 6weeks before 
taking investigational drug. In case of oophorectomy  alone, onl y when the 
reproductive status of the woman has been confirmed by  follow up hormone level 
assessment.
Male sterilization (at least 6 months prior to screening). For female subjects on the 
study , the vasectomized male partner should be the sole partner for that subject.
Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical 
/vault caps). For the United Kingdom of Grea t Britain and Northern Ireland ( UK): 
with spermicidal foam/gel/film/cream/vaginal suppository .
Placement of an intrauterine device (IUD) or intrauterine s ystem (IUS).
Note that sy stemic hormonal contraception (e.g. oral contraception or hormone 
vaginal ring) is not an acceptable means of contraception due to the potential 
influence of QBW251 in decreasing the s ystemic levels of these hormones and 
therefore making them ineffective (see Section 6.2.1.2 ).
If local regulations deviate from the contraception methods listed above to prevent 
pregnancy , local regulations apply  and will be described in the ICF.
Women are considered post -menopausal and not of childbearing potential if they  have had 
12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. 
age appropriate history  of vasomotor sy mptoms) or have had surgical bilateral 
oophorectom y (with or without hy sterectomy ), total hy sterecto my or bilateral tubal 

Novartis Confidential Page 39
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
Investigational/ 
Control Drug
(Name and 
Strength)Pharmaceutical 
Dosage FormRoute of 
AdministrationSupply Type Sponsor (global 
or local)
QBW251 25 mg 
b.i.d.Capsule Oral use Double -blind 
supply; bottlesSponsor global
QBW251 Placebo 
b.i.d.Capsule Oral use Double -blind 
supply; bottlesSponsor global
All capsules are of identical appearance to e nsure blinding. *Following discontinuation of the QBW 251 
450 mg b.i.d. arm, this dose strength is not supplied to patients any more.
6.1.2 Additional study treatments
All patients will be required to have been on a triple therapy  regimen (LABA/L AMA/ ICS) for 
at least 3months prior to screening. Patients will then be switched at the Run-In 1visit to a 
standard background triple therap y:
Either a once dail y fixed triple combination of fluticasone furoate1, vilanterol, and 
umeclidinium (100 µg/25 µg/62.5 µg, respectively ) using a dry  powder inhaler or
A once dail y dual fixed combination of fluticasone furoate1/vilanterol (100 µ g/25 µg, 
respectivel y) with once daily  umeclid inium (62.5 µ g), both using dry  powder inhalers.
The selection of the standard background triple therap y will be determined by the availabilit y 
in the country  of the triple therap y option at study  start. Either standard background triple 
therap ywill be taken in the morning approximately  between 7 and 10 a.m. Patients will be 
instructed not to take the triple therap y (LABA/LAMA/ ICS) within 24 hours prior to any 
spirometric assessment visit. If a patient has to use triple therapy  (LABA/LAMA/ ICS) within 
24 hours prior to an y spirometric assessment, the visit may  need to be rescheduled.
The triple therapy  will be supplied to the investigator sites locall y by Novartis or provided by 
the study  center and reimbursed by  Novartis.
Sites 
will be instructed to record the triple therapy  information in the corresponding COPD 
eCRF page.
In addition, patients are provided with a short acting beta agonist (salbutamol 100 µ g or 
albuterol 90 µg) to use as rescue medication as needed (see Secti on 6.2.3 for rescue medication 
further information).
1Fluticasone is a substrate of CYP3A and therefore systemic levels of fluticasone could be 
influenced by QBW251 administration. However, the efficacy  of inhaled fluticasone is not 
expected to be impact ed due to the delivery  directly  to the lungs.
6.1.3 Treatment arms/group
Subjects will be assigned at Day 1 to 1of the following 6treatment arms in a ratio of 2:2:1:1:1:2:
QBW251 450 mg b.i.d. (discontinued)
QBW251 300 mg b.i.d.
QBW251 150 mg b.i.d.
QBW251 75 mg b.i.d.

Novartis Confidential Page 40
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
QBW251 25 mg b.i.d.
Matching placebo to QBW251 b.i.d.
Following discontinuation of the 450 mg b.i.d. treatment arm, subjects will no longer be 
randomized to this arm, resulting effectively in a 2:1:1:1:2 randomization ratio (300 mg b.i.d. : 
150 m g b.i.d. : 75 mg b.i.d. : 25 mg b.i.d. : placebo).
6.1.4 Treatment duration
The planned duration of treatment in the study with QBW251 or matching placebo is 24 weeks 
(Day  1 to Week 24). Subjects may be discontinued from treatment earlier at the discretion of 
the investigator if patient safet y and well
-being are compromised, if unacceptable side-effects 
occur, or if the subject withdraws informed consent (refer to Section 9.1.1 and Section 6.5.1
for more information).
Patients will be switched to a standardized COPD maintenance background therap y 
(LABA/LAMA/ICS) at the Run-In 1  visit and will continue throughout the study until the 
Follow -Upvisit.
Patients will receive rescue medication SABA at Screening, which will be used as needed until 
the Follow -Upvisit.
6.2 Other treatment(s)
6.2.1 Concomitant therapy
All medications, procedures and significant non -drug therapies (includin g physical therap y and  
blood transfusions) administered after the subject was enrolled into the study must be recorded 
in the concomitant medications/ significant non -drug therapies or procedures eCRF page.
Each concomitant drug must be individually  assesse d against all exclusion criteria/prohibited 
medication. Please note that the lists provided below may not be exhaustive. If in doubt the 
investigator should contact the Novartis Medical Monitor before randomizing a subject or 
allowing a new medication to be started. If the subject is alread y enrolled, contact Novartis to 
determine if the subject should continue participation in the study .
6.2.1.1 Permitted concomitant therapy  requiring caution and/or action
Table 6-2provides an overvie w of medications permitted under certain conditions, including 
bronchodilator medications, which need to be withheld for certain timeframes prior to 
spirometry  assessments on visit day s.

Novartis Confidential Page 41
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
Table 6-2 Medications permitted under certain conditions
Rationale /Group Medication Prohibition period /
Washout periodAction taken
Study-supplied COPD 
maintenance 
background therapyVilanterol, 
Umeclidinium, 
Fluticasone furoateHold treatment for 24 
hours ( ±2 hours) prior 
to each 
FEV 1/spirometry 
measurement on visit 
days.If possible, postpone 
spirometry  
measurement on the 
same 
dayuntil thewashout 
criterion is 
fulfilled. Trough 
spirometry  (-45 min 
and -15 min 
assessments) should 
bedone within 1 0 to 
14 hours from dosing 
on the previous 
evening.
Otherwise, postpone 
visit to the next day 
where washout criteria 
can be fulfilled.
Study-supplied rescue 
medication onlyShort- Acting Beta -2 
Agonists (SABA)Hold treatment at least 
6 hours p rior to each 
FEV 1/spirometry 
measurement.If possible, postpone 
spirometry  
measurement on the 
same day until the 
washout criterion is 
fulfilled. Trough 
spirometry  (-45 min 
and -15 min 
assessments) should 
be done within 1 0 to 
14 hours from dosing 
of investigational drug 
on the previous 
evening.
Otherwise, postpone 
visit to the next day 
where washout criteria 
can be fulfilled.
Systemic antibiotics Antibiotics Systemic antibiotics 
are allowed for short-
term (up to 14 days) 
treatment of acute 
infections , or are 
allowed for the 
treatment of acute 
exacerbations (but not 
as permanent 
prophylactic 
treatment).Discontinue study drug 
if permanent sy stemic 
antibiotic treatment 
cannot be 
discontinued.

Novartis Confidential Page 42
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
Rationale /Group Medication Prohibition period /
Washout periodAction taken
Topical treatment (e.g. 
use of intraocular, 
intraconjunctival 
antibiotic treatments, 
topical use of creams, 
etc.) is permitted.
QBW251 may  inhibit the metabolic clearance of co -medications metabolized by  CYP1A2 and 
induce CYP2B6. In addition, QBW251 is a time-dependent inhibitor and inducer of CYP3A4/5. 
Drugs that are sensitive substrates of CYP1A2 have potential for an increase in exposure with 
QBW251 due to inhibition of CYP1A2 and decrease in exposure due to induction of CYP2B6. 
The net effect of QBW251 on CYP3A4 is anticipated to be induction based on results ofan oral 
contraceptive study  resulting in a decrease in exposure.
Weak in vitro inhibition of BCRP, OAT1/3, OATP1B1, OATP1B3, UGT1A1 and UGT2B7 
was also observed. QBW251 may increase the exposure of drugs, which are substrates of the 
mentioned pathway s.
These drugs are listed in Table 6-3and can be used when indicated and no alternative treatment 
is available. Safet y and efficacy  of drugs should be monitored accordingl y.
The following lists are not considered exhaustive and labels for individual drugs should be 
referred to.
Table 6
-3 Medications the exposure of which may  be modified by  co-
administration with QBW251
Medications that may have decrea
sed exposure due to co -administration with QBW 251
Sensitive Substrates of CYP2B6 bupropion, efavirenz .
Narrow therapeutic index substrates of CYP3A alfentanil1, astemizole, cisapride, cyclosporine, 
dihydroergotamine, ergotamine, fentanyl, 
pimozide, quinidine, sirolimus1, tacrolimus1, 
terfenadine1.
Sensitive substrates of CYP3A alpha -dihydroergocryptine, alfentanil, 
almorexant, alisoporivir, aplaviroc, aprepitant, 
atazanavir, atorvastatin, avanafil, bosut inib, 
brecanavir, brotizolam, buspirone, capra virine, 
casopitant, cobimetinib, conivaptan, danoprevir, 
darifenacin, darunavir, dasatinib, dronedarone, 
ebastine, eletriptan, elvitegravir, eplere none, 
everolimus, felodipine, grazoprevir, ibrutinib, 
indinavir, isavuconazole, ivabradine, ivacaftor, 
levome thadyl, lomitapide, lopinavir, lovastatin, 
lumefantrine, lurasidone, maraviroc, midazolam, 
midostaurin, naloxegol, neratinib, nisoldipine, 
paritaprevir, perospirone, quetiapine, 
ridaforolimus, saquinavir, sildenafil, simeprevir, 
simvastatin, sirolimus, tac rolim us, terfenadine, 
ticagrelor, tilidine,tipranavir, tolvaptan, triazolam, 
ulipristal, vardenafil, venetoclax, vicriviroc, 
voclosporin.

Novartis Confidential Page 43
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
Medications that may have increased exposure due to co -administration with QBW 251
Sensitive Substrates of CYP1A2 alosetron, caffeine, duloxetine, melatonin, 
pirfenidone, ramelteon, selegiline, tacrine, 
tasimelteon .
BCRP substrates atorvastatin daunorubicin, doxorubicin, ethinyl 
estradiol, hematoporphyrin, imatinib, 
methotrexate1, mitoxantrone, pitavastatin1, 
rosuvastatin1, SN-38 (irinotecan), simvastatin, 
sulfasalazine, sofosbuvir1, sulfasalazine1, 
tenofovir1, topotecan1.
OAT Substrates acyclovir, adefovir, anagliptin, beta -lactam 
antibiotics, bumetanide, captopril, cefonicid, 
cefaclor, cephradine, cimetidine , 
chlorothiazide, cidofovir, dapagliflozin, 
famotidine, furosemide, ganciclovir, ibuprofen, 
methotrexate, olmesartan, pemetrexed, 
pravastatin, pitavastatin, quinaprilat, ranitidine,
rosuvastatin, tenofovir, tetracy cline, topotecan -
hydroxyl acid, valsartan, zidovudine, 
zonampanel.
OATP substrates aliskiren, ambrisentan, anacetrapib, asunaprevir, 
atenolol, atrasentan, atorvastatin, bosentan, 
bromociptine, caspofungin, cerivastatin, 
celiprolol, danoprevir, digoxin, docetaxel, 
eliglustat, empangliflozin, ezeti mibe, fimasartan, 
fexofenadine, fluvastatin, glyburide, maraviroc, 
methotrexate, montelukast, olmesartan, 
paclitaxel, pirataprevir, pitavastatin, pravastatin, 
repaglinide, rifampin, rosuvastatin, saquinavir, 
simvastatin acid, simvastatin, SN -38 (irinotecan ), 
telmisartan, ticlopidine, thyroxine, valsartan.
UGT1A1 Substrates abacavir, acetaminophen, atorvastatin, axitinib, 
belinostat,buprenorphine, carvediol, diclofenac, 
dolutegravir, desvenlafaxine succinate, 
eltrombopag, elvitegravir, estradiol, etoposide,
ezetimibe, ezogabine, febuxostat, flurbiprofen, 
fluvastatin, furosemide gemfibrozil, indacaterol, 
indomethacin, irinotecan, ketoconazole, 
levothyroxine, losartan, lovastatin, morphine, 
muraglitazar, m ycophenolate mofetil, 
mycophenolic acid, naltrexone, naproxen, 
paracetamol, raloxifene, raltegravir, rosuvastatin, 
simvastatin, iri notencan, suprofen, telmisartan.

Novartis Confidential Page 44
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
UGT2B7 Substrates almokalan, ambrisentan, atorvastatin, 
buprenorphine, canagliflozin, carabamazepine, 
carvediolol, chloramphenicol, clofibric acid, 
codeine, c yclosporine, dabigatran etexilate, 
dapagliflozin, diclofenac, empagliflozin, 
entacapone, epirubicin, etodolac, ezetimibe, 
febuxostat, fenofibrate, fenoprofen, flurbiprofen, 
fluvastatin, furosemide, gemfibrozil, 
hydromorphone, ibuprofen, indomet hacin, 
ketoprofen, lamotrigine, lorazepam, lorazepam, 
losartan, lovastatin, methadone, midazolam, 
mitiglinide, morphine, m ycophenolate mofetil, 
mycophenolic acid, nalorphine, naloxone, 
naltrexone, naproxen, oxazepam, pitavastatin, 
sertraline, silodosin, si mvastatin, suprofen, 
tacrolimus, tapentadol, temazepam, zaltoprofen, 
zidovudine .
Medications in this table were identified as substrates based on either in vivo or in vitro data. 
1Also considered sensitive CYP3A substrates. Budesonide and fluticasone are also sensitive 
substrates of CYP3A, but have not been listed here since these are prohibited medications (except for 
study -supplied COPD background medication containing fluticason e, as specified in Section 6.1.2 , or 
as sy stemic corticosteroids for the treatment of COPD exacerbations, as specified in Section 8.3.9 ). 
Furthermore, patients should be instructed not to ta ke grapefruit, Seville oranges or their juice for 14 
days prior to dosing, during treatment and until 7 days following the last dose, due to an ingredient that 
is an inhibitor sensitive substrate of CYP3A.
6.2.1.2 Systemic contraceptives
Systemic contraceptives such as listed in Table 6-4are not an acceptable means of contraception 
(refer also to definition of acceptable effective contraception methods in Section
5.2), since 
these drugs may be ineffective due to decreased exposure in combination with QBW251 and 
result in contraceptive failure. These drugs may be taken for other 
indications (e.g. osteoporosis 
prophy laxis); the efficacy of the treatment may be impaired by low system ic availability , though, 
and should be monitored.
Table 6-
4 Examples of contraceptives not recommended for sy stemic use (not 
acceptable as means of contraception as efficacy may be 
compromised by  QBW251 administration)
Medication Period during which 
contraceptive effect may be 
compromisedAction taken

Novartis Confidential Page 45
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
Drospirenone
Ethinyl estradiol
Etonogestrel
Levonorgestrel
Medrox yprogesterone acetate
Norelgestromin
Norethindrone
Norgestimate
NorgestrelUse of these drugs is not 
prohibited, but in combination 
with QB W251 these may  no 
longer constitute means of 
contraception, and thus their 
use does not fulfill the 
requirements of contraception 
stipulated in the exclusion 
criteria ( risk of contraceptive 
failure). Patient is at risk to 
experience a pregnanc y due to 
the interaction between 
systemic contraceptive and 
QBW251.Avoid concurrent 
administration; for alternative 
methods of contraception refer 
to exclusion criterion #28.
6.2.2 Prohibited medication
Use of the treatments display ed in the below table is NOT allowed after the onset of the 
prohibition period as indicated in Table 6-5and Table 6-6. Should administration of one of 
these drugs during the course of the treatment period be required, study  treatment should be 
discontinued as described in the “Action to be taken” column.
Table 6
-5 Prohibited medication
Rationale /Group Medication1Prohibition period Action to be taken
Medications with a 
narrow therapeutic 
range and potential for 
increased exposure 
with QB W251 due to 
inhibition of CYP1A2:Theophylline2
TizanidineDiscontinue treatment 
at least 1 week prior to 
Day 1Discontinue study 
treatment.
Medications lacking 
information on 
metabolizing enzy mes:Pirbuterol Discontinue treatment 
at least 1 week prior to 
Day 1Discontinue study 
treatment.
Strong uridine 
diphosphate 
glucuronosyl 
transferase (UGT) 
inhibitors, which will 
potentially increase 
systemic 
concentrations of 
QBW251Mefenamic acid
Probenecid
Valproic acidDiscontinue treatment 
at least 1 week prior to 
Day 1Concurrent 
administration must be 
avoided; discontinue 
study treatm ent.
Mucolytics Acetylcysteine
Ambroxol
Bromohexine
ErdosteineDiscontinue treatment 
prior to or on Run -In 1.Concurrent 
administration must be 
avoided to ensure 
reliable assessment of 
symptoms.
Antibiotics (long -term 
maintenance)3Azithrom ycin
Erythrom ycin
DoxycylineDiscontinue treatment 
at least 30 days prior 
to Run -In 1.Discontinue study 
treatment.

Novartis Confidential Page 46
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
1 The medications listed here are prominent examples of the group of medications fulfilling the 
rationale, but all drugs fulfilling the rationale for exclusion are not allowed (e.g. any mucolytic drug).
2Note that theophylline has to be terminated 7 days prior to Run -In 1 due to stipulations for prohibited 
COPD medications ( Table 6 -6) and is listed here for completeness of information only. 
3Most frequently used antibiotics are listed only. However, all long -term sy stemic antibiotic treatment 
is excluded, regardless of the drug. For use of short term antibiotics for COPD exacerbations: prior to 
the study refer to the exclusion criteria 9 and 10, during the study, refer to Table 6-2. Any other use of 
short term antibiotics prior to the study does not require a wash- out.
Table 6-6 Prohibited COPD -related medications
Class of medication1Minimum washout period prior to Run In 1 
Long- acting muscarinic antagonists (LAMA) 
(other than as ingredient of study background 
therapy)12 hours for twice -daily LAMAs
24 hours fo r once -daily LAMAs
Short- acting muscarinic antagonists (SAMA) 6 hours
Fixed combinations of long- acting β 2agonists 
and inhaled corticosteroids (LABA/ICS)(other 
than as ingredient of study background therapy )12 hours for twice -daily combinations
24 hours for once -daily combinations
Long- acting β 2agonists (LABA)(other than as 
ingredient of study background therapy)12 hours for twice -daily LABAs
24 hours for once -daily LABAs
Short- acting β 2agonists (SABA) (other than trial 
rescue medication)6 hours
Oral phosphodiesterase -IV inhibitor 7 days
Xanthines (any formulation) 7 days
Systemic corticosteroids 30 days
Inhaled corticosteroids (other than as ingredient 
of study -supplied background therapy)12 hours
Intra-muscular depot corticosteroids 3 months
1 This table is not considered all -inclusive. Medications should be assessed for adherence to the 
indication and other inclusion/exclusion criteria. These medications are also prohibited if administered 
for other indications. This should be taken i n the context of COPD severity as well as planned 
comparator arms. All these medication listed under Table 6 -6may be permitted for the treatment of a 
COPD exacerbation during the study except intra- muscular depot corticosteroids If intra -muscular 
depot corticosteroid treatment is required, the patient should be withdrawn from the study treatment. 
Medications unde r Table 6 -5are not permitted and should follow the action as listed in the table .
6.2.3 Rescue medication
At Screening and whenever needed thereafter, patients will be provided with a short acting 
beta 
agonist (salbutamol 100 µ g or albuterol 90 µ g) inhaler to use as rescue medication on an “as 
needed” basis throughout the study . Nebulized salbutamol/albuterol is not allowed as rescue 
medication throughout the trial. No other rescue medication is permitted.
The use of rescue medicatio n (number of puffs taken in the previous 12 hour s) will be recorded 
(once in the morning and once in the evening) by the patient, in the electronic patient diary . The 
rescue salbutamol/albuterol provided at Screening for use during the study  should not be 
recorded on the COPD related prior concomitant page of the eCRF.
The rescue medication will be supplied to the investigator sites locall y by N ovartis or provided 
by the study  center and reimbursed by  Novartis.

Novartis Confidential Page 47
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
6.3 Subject numbering, treatment assignment, randomization
6.3.1 Subject numbering
Each subject is identified in the study  by a Subject Number (Subject No.), that is assigned when 
the subject is first enrolled for screening and is retained as the primary identifier for the subject 
throughout his/her entire participation in the trial. The Subject No. consists of the Center 
Number (Center No.) (assigned by Novartis to the investigative site) with a sequential subject 
number suffixed to it, so that each subject is numbered uniquel y across the entire database. 
Upon signing the informed consent form, the subject is assigned to the next sequential Subject 
No. available.
6.3.2 Treatment assignment, randomization
At Day 1, all eligible patients will be randomized via Interactive Response Technology  (IRT) 
to one of the treatment arms. The investigator or his/her delegate will contact the IRT after 
confirming that the patient fulfills all the inclusion/exclusion criteria. The IRT will assign a 
randomization number to the patient, which will be used to link the patient to a treatm ent arm 
and will specify  a unique medication number for the first package of investigational treatment 
to be dispensed to the patient. The randomization number will not be communicated to the caller.
The randomization numbers will be generated using the following procedure to ensure that 
treatment assignment is unbiased and concealed from patients and investigator staff. A patient 
randomization list will be produced by the IRT supplier using a validated system that automates 
the random assignment of patient numbers to randomization numbers. These randomization 
numbers are linked to the different treatment arms, which in turn are linked to medication 
numbers. A separate medication list will be produced by or under the responsibility  of Novartis 
Global Clinica l Supply  using a validated system that automates the random assignment of 
medication numbers to packs containing the investigational drug(s).
Randomization will be stratified by smoking status (current or ex-smoker )and severit y of 
airflow limitation (FEV 1≥ 30% to <50% and ≥ 50% to < 80%) , as assessed at Run- In 1.
The randomization scheme for patients will be reviewed and approved by a member of the 
Randomization Office.
6.4 Treatment blinding
Subjects, investigator staff, persons performing the assessments, and Clinical Trail Team (CTT )
will remain blind to the identity of the treatment from the time of randomization until database 
lock, using the following methods: 
(1) Randomization data are kept strictly  confidential until the time of unblinding, and will not 
be accessible by anyone else involved in the study  with the following exceptions: PK analy st, 
independent statistician and programmer supporting the DMC and, if deemed necessary  by the 
DMC, the DMC members.
(2) the identit y of the treatments will be concealed by the use of study  treatment that are all 
identical in packaging, labeling, schedule of administration, appearance, taste and odor.

Novartis Confidential Page 48
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
The randomization codes associated with subjects from whom PK samples are taken will be 
disclosed to PK analy sts who will keep PK results confidential until data base lock.
Unblinding will occur in the case of subject emergencies, in case of a DMC request as an 
outcome of their evaluation and at the conc lusion of the study .
Unblinding of predetermined CTT members will occur at the time of the efficacy  interim 
analysis. The study  will then continue under the management of a separate blinded team. In 
order to maintain the integrity  of the study  data, separa te blinded team members will not have 
access to any unblinded data. The detailed procedures will be described in a separate charter. 
The remainder of members including clinical study  team, subjects, investigator staff, persons 
performing the assessments wi ll remain blinded until the final database lock.
6.5 Dose escalation and dose modification
Investigational or other study  treatment dose adjustments are not permitted. Dose temporar y 
interruptions are permitted under specific circumstances described in Section 6.5.1.
6.5.1 Dose modifications
Study  drug dose temporary  interruptions are not permitted unless the investigator considers a 
temporary  interruption is necessary  for the treatment of an adverse event (if the 
adverse event 
grade is severe and suspected to be related to the investigational study  drug should be 
permanentl y discontinued as described in Section 9.1.1 ).
Any interruption of study  medication for more than 5consecutive days during the treatment 
period should be discussed with the local Novartis Medical Monitor to review the patient’s 
eligibility  to continue in the trial.
The study  drug dose interruptions must be recorded in the Dosage Administration Record eCRF.
6.5.1.1 Dose adjustments for QTcF prolongation
In case of QTcF > 500 msec, (or QTcF prolongation > 60 msec from baseline)
Assess the quality  of the ECG recording and the QT value and repeat, if needed .
Interrupt investigational treatment.
Determine the serum electroly te levels (in particul ar hy pokalemia, hy pomagnesemia). If 
abnormal, correct abnormalities.
If possible, collect a time -matched PK sample on that visit (if not alread y scheduled/taken 
per Table 8-1) and record time and date of last study  treatment in take.
If QTcF confirmed b
y the Central Reading > 500 msec: 
Permanently  discontinue the investigational treatment.
Consult with a cardiologist (or qualified specialist).
Increase cardiac monitoring as indicated, until the QTcF returns to ≤ 480 msec .
Review concomitant medication use for other causes for QT prolongation (refer to 
http://www.qtdrugs.org for known QT prolonging drugs), and for drugs with the 
potential to increase the risk of drug exposure related QT prolongation .
Check the dosing schedule and treatment compliance.

Novartis Confidential Page 49
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
6.5.2 Follow -up for toxicities
Not applicable
6.6 Additional treatment guidance
6.6.1 Treatment compliance
Study  drug compliance should be assessed by the investigator and/or center personnel at all 
visits. The Investigator or designee will collect, from the patient, the used/unused 
investigational study  drug and packaging at all dispensing visits. Study  drug compliance will 
be assessed from the capsule count (unused medication) and from information provided by  the 
patient and/or caregiver. This infor mation should be captured in the source documentation. The 
total number of doses of investigational treatment administered since the last dispensing visit 
should be captured in the source documentation, and the start and end date of investigational 
study  drug and any interruptions of investigational treatment of more than 5 days or any 
interruption of investigational treatment due to an Adverse Event will be recorded on the eCRF. 
Patient will also be instructed to report any missing doses of investigational study  drug in the 
eDiary .
The number of puffs of rescue medication inhaled will be recorded twice daily b y the patient in 
the eDiary . The patient will be instructed accordingl y at Screening (when he/she is provided 
with the eDiary  and the use of rescue medication is discussed). The use of rescue medication 
will be reviewed at each visit and data from the eDiary  downloaded at each visit. Where 
necessary , the Investigator will discuss compliance/documentation issues regarding rescue 
medication use with the p atient.
The COPD maintenance background therapy  compliance will also be monitored at all 
dispensing visits and information captured in the source documents at site. Information on the 
start date, end date and interruptions of more than 3days or due to an Adverse Event must be 
captured in the eCRF. Any  compliance issues must be discussed with the patient.
The investigator must promote compliance by instructing the subject to take the study  treatment 
exactly  as prescribed and by stating that compliance is necessary  for the subject’s safet y and 
the validity  of the study . The subject must also be instructed to contact the investigator if he/she 
is unable for an y reason to take the study  treatment as prescribed . 
6.6.2 Emergency  breaking of assigned treatment code
Emergency  code breaks must only be undertaken when it is required to in order to treat the 
subject safel y. Most often, study  treatment discontinuation and knowledge of the possible 
treatment assignments are sufficient to treat a study  subject who presents with an emergency  
condition. Emergency  treatment code breaks are performed using the IRT. When the 
investigator contacts the system to break a treatment code for a subject, he/she must provide the 
requested subject identifying information and confirm the necessity to break the treatment code 
for the subject. The investigator will then receive details of the investigational drug treatment 
for the specified subject and a fax or email confirming this information. The system will 
automatically  inform the Novartis monitor for the site and the study  team that the code has been 
broken.

Novartis Confidential Page 50
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
It is the investigator’s responsibility  to ensure that there is a dependable procedure in place to 
allow access to the IRT/code break cards at any time in case of emergency . The investi gator 
will provide:
protocol number
subject number
In addition, oral and written information to the subject must be provided on how to contact 
his/her backup in cases of emergency , or when he/she is unavailable, to ensure that un blinding 
can be performed a t any time.
Following emergency  unblinding, the subject will be permanently  discontinued from the study 
investigational treatment as described in Section 9.1.1.
6.7 Preparation and dispensation
Each study  site will be supplied with investigational study  drug in packaging as described under 
investigational and control drugs section.
A unique medication number is printed on the study
 medication label.
Investigator staff will identify  the study  medication kits to dispense to the subject by contacting 
the IRT and obtaining the medication number(s). The study medication has a 2 -part label (base 
plus tear-off label), immediately  before dispensing the medication kit to the subject, site 
personnel will detach the outer part of the label from the packaging and affix it to the source 
document.
Investigational study  drug consists of oral dispensation capsules and no preparation prior to 
dispensation is required.
6.7.1 Handling of study treatment and additional treatment
6.7.1.1 Handling of study  treatment
Investigational study  treatment must be received by a designated person at the study  site, 
handled and stored safely  and properl y and kept in a secured location to which only the 
investigator and designated site personnel have access. Upon receipt, all investigational study  
treatment must be stored according to the instructions specified on the labels and in the 
Investigator’s Brochure. Clinical supplies are to be dispensed only in accordance with the 
protocol. Technical complaints are to be reported to the respective Novartis Country  
Organization Quality  Assurance.
Medication labels will be in the local language and comply with the legal requirements of each 
country . They  will include storage conditions for the study  treatment but no information about 
the subject except for the medication number .
The investigator must maintain an accurate record of the shipment and dispensing of study 
treatment in a drug accountability  log. Monitoring of drug accountability  will be performed by 
monitors during site visits or remotely and at the completion of the tr ial. Subjects will be asked 
to return all unused study  treatment and packaging at the end of the clinical trial or at the time 
of discontinuation of study treatment.

Novartis Confidential Page 51
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
At the conclusion of the study , and as appropriate during the course of the study , the investigator 
will return all unused investigational study  treatment, packaging, drug labels and a copy  of the 
completed drug accountability  log to the Novartis monitor or to the Novartis address provided 
in the investigator folder at each site.
6.7.1.2 Handling of additional treatment
Additional study  treatment (COPD maintenance background therapy  and rescue medication) 
must be received by a designated person at the study  site, handled and stored safel y and properl y 
and kept in a secured location to which only the investigator and designated site personnel have 
access. Upon receipt, the additional study  treatment must be stored according to the instructions 
specified on the labels. Clinical supplies are to be dispensed only in accordance with the 
protocol.
The inves tigator must maintain a record of the shipment and dispensing of the additional study 
treatment in a drug accountability  log. Monitoring of drug accountability  will be performed by 
monitors during site visits or remotely and at the completion of the trial. Subjects will be asked 
to bring all unused study  treatment to the site at all visits including the time of discontinuation 
of study  treatment to allow for medication use review.
6.7.2 Instruction for prescribing and taking study treatment
The following are the instructions for the investigational drug (QBW251/placebo):
QBW251/ placebo is an oral capsule .
One capsule should be taken twice a day  at approximately  the same time each day , with 
about 12 hours between each dose administration (approximately  in the morn ing between 
7 and 10 a.m. and in the evening between 8 and 11 p.m.).
It is recommended not to take the investigational drug in together with high- fat meals.
The definition of high -fat meals follows the definition suggested by  the FDA in the draft 
guidance on Assessing the Effects of Food on Drugs in INDs and NDAs ( FDA 2019): a 
meal containing at least 1000 kcal (4184 kJ), and at least 50% 
of that energy  content from 
fat. 
An example of a high fat meal would be:
oTotal nut ritional energy  value: 1000 kcal
of which from proteins: 150 kcal
of which from carboh ydrates: 250 kcal
of which from fats: 600 kcal.
Patients can drink water as needed.
Patients should be instructed not to take grapefruit, Seville oranges or their juice f or 14 
days prior to dosing, during treatment and until 7 day s following the last dose as these 
products are considered inhibitors of CYP3A.
If vomiting occurs during the course of treatment, patients should be instructed not to take 
the study  drug again be fore the next scheduled dose.
Patients should be instructed not to make up missed doses.
Subjects should be instructed to swallow whole capsules and not to chew or open them.

Novartis Confidential Page 52
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
Instructions for the COPD maintenance background therapy  and rescue medication should be 
according to the respective product label.
On study  visit days, patients should be reminded not to take either the investigational drug 
(QBW251/placebo) or the COPD maintenance background therapy  doses prior to the site visit 
to ensure compliance with the pre-dose PK sampli ng procedure and spirometry  pre-dose 
measurements. The morning dose on the visit days should be taken after the pre-dose PK 
sampling and spirometry assessments have been completed within 15 min approximately .
Of note, spirometry  on visit day s shall be conducted
10-14 hours after the last intake of investigational drug on the evening before, and
22-26 hours after the last inhalation of COPD background medication on the morning
before (see also 
Section 8.3.2).
7 Informed consent procedures
Eligible subjects may  only  be included in the study  after providing (witnessed, where required 
by law or regulation), Institutional Review Board/I ndependent Ethics Committee (IRB/IEC )-
approved informed consent.
If applicable, in cases where the subject's representative(s) gives consent (if allowed according 
to local requirements), the subject must be informed about the study  to the extent possible given 
his/her understanding. If the subject is capable of doing so, he/she must indicate agreement by 
personall y signing and dating the written informed consent document.
Informed consent must be obtained before conducting any study-specific procedures (e.g. all of 
the procedures described in the protocol). The process ofobtaining informed consent must be 
documented in the subject source documents.
Novartis will provide to investigators in a separate document a proposed informed consent form 
that complies with the ICH Good Clinical Practice (GCP ) guidelines and regulator y 
requirements and is considered appropriate for this study . Any changes to the proposed consent 
form suggested by the investigator must be agreed by Novartis before submission to the 
IRB/IEC.
Information about common side effects alread y known about the investigational drug can be 
found in the Investigator's Brochure (IB). This information will be included in the subject 
informed consent and should be discussed with the subject during the study  as needed. Any new 
information regarding the safet y profile of the investigational drug that is identified between IB 
updates will be communicated as appropriate, for example, via an Investigator Notification (IN)
or an aggregate safet y finding. New information might require an update to the informed 
consent and then must be discussed with the subject.
Women of childbearing potential must be informed that taking the study  treatment may involve 
unknown risks to the fetus if pregnancy  were to occur during the study  and agree that in order 
to participate in the study they must adhere to the contraception requirements. They  shall be 
informed that contraception should be continued for at least 7 day s following the last intake of 
QBW251/placebo. Patients completing the study  as planned are required t o exercise acceptable 

Novartis Confidential Page 53
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
effective contraception during their entire stud y participation; thus, the above period is covered 
by the follow- up period.
The study  includes optional assessments such as the additional pharmacokinetic sampling 
timepoints at Day 1 and Day 15 . As previously  described, 
each additional data collection activity  may not be conducted in all countries, depending on 
regulatory  acceptability , logistic considerations, and need of participants for the respectiv e 
activity . Any additional data collections 
require a separate signature, if the subject agrees to 
participate. It is required as part of this protocol that the Investigator presents the available 
options to the subjects, as permitted by local governing regulations. The process for obtaining 
consent should be exactly the same as described above for the main informed consent.
Declining to participate in 1or more of these optional assessments (  additional 
pharmacokinetic sampling) will in no way  affect the subject’s ability  to participate in the main 
research stud y.
A copy of the approved version of all consent forms must be provided to Novartis/sponsor after 
IRB/IEC approval.
Subjects might be asked to complete an optional questionnaire to provide feedback on their 
clinical trial experience (see Section 8.5.4).
8 Visit schedule and assessments
The assessment schedule table (Table 8
-1) lists all of the assessments and indicates with an “X”,
the visits when they are performed. All data obtained from 
these assessments must be supported 
in the subject’s source documentation.
Patients should be seen for all visits/assessments as outlined in the assessment schedule or as 
close to the designated day/time as possible. Missed or rescheduled visits should not lead to 
automatic discontinuation. Subjects who prematurely  discontinue the study  for any reason 
should be scheduled for a visit as soon as possible, at which time all of the assessments listed 
for the 
final visit will be performed. At this final visit, all dispensed investigational product 
should be reconciled, and the adverse event and concomitant medications recorded on the eCRF.
Below Table 8-2will describe the or der and timepoints for all the timed assessments in all the 
visits scheduled. If the subject is participating in the additional PK timepoints at Day 1 and Day 
15, refer to the Table 8-
3for these visits.

Novartis Confidential Page 54
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
Table 8-1 Assessment Schedule
Period Screening Run-In Treatment Follow -Up Unscheduled
Visit Name ScreeningRun-In 
1Run-In 
2Day 
1Week 
2Week 
4Week 
8Week 
12Week 
16Week 
20Week 24 PSW1Follow -Up Unscheduled
Days -21 -14 1 1 15 29 57 85 113 141 169 - 197 -
Informed consent X
Demography X
Physical Examination X X X
Body Height X
Body W eight X X X
Vital Signs X X X (X)5X X X X X X X X X
Medical history/current 
medical conditions2 X
COPD exacerbation 
historyX
Smoking history X
Smoking status (X)3X X
Inclusion /Exclusion 
criteriaX X X
Concomitant 
medicationsX X X X X X X X X X X X X
Dispensation of rescue 
medicationX X X X X X X X X
Dispensation of 
standard background 
triple therapyX X X X X X X X
Dispensation of study 
drugX X X X X X
Spirometry X X X X X X X X X X
Spirometry Reversibility 
TestX

Novartis Confidential Page 55
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
Period Screening Run-In Treatment Follow -Up Unscheduled
Visit Name ScreeningRun-In 
1Run-In 
2Day 
1Week 
2Week 
4Week 
8Week 
12Week 
16Week 
20Week 24 PSW1Follow -Up Unscheduled
Days -21 -14 1 1 15 29 57 85 113 141 169 - 197 -
Electrocardiogram 
(ECG)4 X X X5X6X X X X X X6X X
COPD Assessment Test 
(CAT)7 X
St. George's Respiratory 
Questionnaire7 X X X X
Patients Global 
Impression of Severity 
Scale (PGI -Sgeneral 
question)7X X X X
Patients Global 
Impression of Severity 
Scale (PGI -Sspecific 
question)7X X X X
Cough And Sputum 
Assessment 
Questionnaire (CASA-
Q)7X X X X
e-Diary - rescue 
medication usefrom
Day -21X X X X X X X X Xuntil Day 
169until 
PSW
e-Diary - EXACT 
Questionnaire8from 
Day -14X X X X X X X Xuntil Day 
169until 
PSW

Novartis Confidential Page 56
Amended Protocol Version 03 (Clean) Protocol No. CQBW 251B2201
Period Screening Run-In Treatment Follow -Up Unscheduled
Visit Name ScreeningRun-In 
1Run-In 
2Day 
1Week 
2Week 
4Week 
8Week 
12Week 
16Week 
20Week 24 PSW1Follow -Up Unscheduled
Days -21 -14 1 1 15 29 57 85 113 141 169 - 197 -
Assessment of 
childbearing potentialS
Pregnancy Test 
(serum)10 X
Pregnancy Test (urine)10X X X X X X X X X X
Hematology X X X X X X X X X X
Clinical Chemistry11X X X X X X X X X X
Urinalysis12X X X X X X X X X X
PK blood collection X13X13X X X X X X13X X14
PK Sub -group
(serial PK sampling)X15X15
Adverse Events X X X X X X X X X X X X X
Serious Adverse Events X X X X X X X X X X X X X
Surgeries & procedures 
reviewX X X X X X X X X X X X X
Contact IVRS /IWRS X X X16X X X X X X X X X X
Study Disposition Page X17X18X19X19X20
Study completion 
informationX21X

Novartis Confidential Page 58
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
Table 8-2 Timed assessments for all visits
Time 
Point1PROs at 
siteUrine 
SampleECG Vital 
Signs3Hemato
-logy/ 
Blood 
Chemis -
trySpiro -
metry4PK 
Blood 
Samp -
ling
Day 1 Prior to -
45 minX
X X2X
Prior to -
45 minRandomization
-45 min X
-45 to -
20 min 
approxi
matelyX X
-15 min X
0 Study drug administered in clinic
3 h X2X
Week 2 Prior to 
Study 
drugX2X
Prior to 
Study 
drugX
0 Study drug administered in clinic
3 h X2X
Week 4 Prior to -
45 minX2X
-45 min X
-45 to -
20 min 
approxi
matelyX X
-15 min X
0 Study drug administered in clinic
Week 8 Prior to -
45 minX2X
-45 min X
-45 to -
20 min 
approxi
matelyX X
-15 min X
0 Study drug administered in clinic

Novartis Confidential Page 59
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
Time 
Point1PROs at 
siteUrine 
SampleECG Vital 
Signs3Hemato
-logy/ 
Blood 
Chemis -
trySpiro -
metry4PK 
Blood 
Samp -
ling
Week 12 Prior to -
45 minX
Prior to -
45 minX2X
-45 min X
-45 to -
20 min 
approxi
matelyX X
-15 min X
0 Study drug administered in clinic
Week 16 Prior to -
45 minX2X
-45 min X
-45 to -
20 min 
approxi
matelyX X
-15 min X
0 Study drug administered in clinic
Week 20 Prior to -
45 minX2X
-45 min X
-45 to -
20 min 
approxi
matelyX X
-15 min X
0 Study drug administered in clinic
Week 24 Prior to -
45 minX
X X2X
-45 min X
-45 to -
20 min 
approxi
matelyX X
-15 min X
0 Study drug administered in clinic
3 h X2X
PSW Prior to -
45 minX
X X2X

Novartis Confidential Page 60
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
Time 
Point1PROs at 
siteUrine 
SampleECG Vital 
Signs3Hemato
-logy/ 
Blood 
Chemis -
trySpiro -
metry4PK 
Blood 
Samp -
ling
-45 min X
-45 to -
20 min 
approxi
matelyX X
-15 min X
0 Theoretical study drug timepoint
3 h
1Time relates to the dose given from spirometry  device at visit unless otherwise specified .
2Triplicate ECG measurements required.
3Systolic /diastolic blood pressure and heart rate .
4A minimum 3 minutes rest period from the beginning of ECG assessments to the start of spirometry  
maneuvers must be observed at all times .
Table 8-3 Timed assessments for Da y 1 and Day  15 for subjects participating in 
the additional PK sampling sub -group (additional PK timepoints)
Time 
Point1PROs at 
siteUrine 
SampleECG Vital 
Signs3Hemato
-logy/ 
Blood 
Chemis -
trySpiro -
metry4PK 
Blood 
Samp -
ling
Day 1 Prior to -
45 minX
X X2X
Prior to -
45 minRandomization
-45 min X
-45 to -
20 min 
approxi
matelyX X
-15 min X
0 Study drug administered in clinic
1 h X
2 h X
4 h X2X
6 h X
8 h X
Week 2 Prior to 
Study 
drugX2X

Novartis Confidential Page 61
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
Time 
Point1PROs at 
siteUrine 
SampleECG Vital 
Signs3Hemato
-logy/ 
Blood 
Chemis -
trySpiro -
metry4PK 
Blood 
Samp -
ling
Prior to 
Study 
drugX
0 Study drug administered in clinic
1 h X
2 h X
4 h X2X
6 h X
8 h X
1Time relates to the dose given from spirometry  device at visit unless otherwise specified
2Triplicate ECG measurements required.
3Systolic /diastolic blood pressure and heart rate
4A minimum 3 minutes rest period from the beginning of ECG assessments to the start of spirometry  
maneuvers must be observed at all times
8.1 Screening
Re-Screening
If a patient fails to meet the eligibility criteria, re -screening is allowed in the cases described in 
Section 5. Re -screening should occur after patient has failed screening. A new patient number 
will be assigned and the site must record the re-screening information in the corresponding 
eCRF and in IRT.
8.1.1 Information to be collected on screening failures
Patients who sign an informed consent 
but fail to continue into the Run-In period for any reason 
will be considered a screen failure. The reason for the screening failure will be entered on the 
screening phase disposition page. The demographic information, informed consent, and 
Inclusion/Exclusion pages must also be completed for screen failure patients. No other data will 
be entered into the clinical database for patients who are screen failures, unless the patient 
experienced a serious adverse event (SAE) during the screening phase (see SAE reporting 
details in Section 10.1.3). I f the patient fails to be randomized, the I RT must be notified within 
2 day s of the screen fail that the patient was not randomized.
8.2 Subject demographics/other baseline characteristics
Patient demographic and other baseline characteristic data to be collected on all subjects 
include:
Year of birth and age
Gender
Race

Novartis Confidential Page 64
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
8.3.5 St George's Respiratory  Questionnaire (SGRQ)
The St. George Respiratory  Questionnaire (SGRQ) will be used to provide the health status 
measurements in this study  (Jones el al 1992 ). The SGRQ will be electronically  completed by 
the patient at the investigator's site at the visits indicated in Table 8-1.
The SGRQ questionnaire should always be completed before an
y other assessments (including 
any other questionnaires) are made to avoid influencing the responses. A detailed guide relating 
to the administrative procedures of the questionnaire are given in Section 16.12 .
Instrument scoring and handling of missing item data will be conducted in accordance with the 
user guide for the SGRQ ( Section 16.12).
The SGRQ contains 50 items divided into 2parts covering 3aspects of health related to COPD : 
Part I covers "Symptoms" and is concerned with respiratory  symptoms, their frequency  and 
severit y; Part II covers "Activity " and is concerned with activities that cause or are limited to 
breathlessness; Part II is also concerned with "Impacts", which covers a range of aspects 
concerned with social functioning and psychological disturbances resulting from airway s 
disease. A score will be calculated for each of these 3subscales and a "Total" score will also be 
calculated. In each case the lowest possible value is zero and the highest 100. Higher values 
correspond to greater impairment of health status.
8.3.6 Patient global impression of severity  (PGI -S: general and specific)
The PGI-S questionnaire will rate the severity  of the respiratory  symptoms (general 
quest ionnaire) and of the cough and mucus (specific questionnaire) in the 
last 7 days and will 
be used to anchor the E -RS total score, E- RS cough and sputum subdomain and CASA -Q.
The PGI -S (a general and a specific question) will be completed electronically  by the patient at 
the investigator's site at the visit schedule indicated in Table 8-1.
An example of the PGI -S is provided in 
Section 16.8.
8.3.7 Cough And Sputum A ssessment Questionnaire (CA SA-Q)
The CASA-Q is a validated questionnaire instrument used to measure cough and sputum 
production, and their impact in patients with chronic obstructive pulmonary  disease (COPD) 
and/or chronic bronchitis ( Crawford et al 2008). I t contains a total of 20 items on a 5 -step scale 
distributed in 4domains: Cough symptoms (COUS; 3 
items), Cough impact (COUI; 8 items), 
Sputum sy mptoms (SPUS; 3 items) and Sputum impact (SPUI ; 6 items).
There are onl y domain scores and no overall score. T he score in each domain ranges from 0 to 
100, with lower score indicating more severe s ymptoms or a higher impact.
The CASA -Q will be completed electronicall y by the patient at the investigator's site at the visit 
schedule indicated in Table 8-1.
An example of the CASA
-Q is provided in Section 16.4.
Below are instructions for all the questionnaires administered at site, including the CASA -Q:
The appropriate language version of the questionnaires will be used in each participating 
country . The same language should be used by a particular patient throughout the study . The 
site personnel administering the 
questionnaire should be familiar with themeasures and the 

Novartis Confidential Page 67
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
8.4 Safet y
Safety  assessments are specified below in with the assessment schedule detailing when each 
assessment is to be performed in Table 8-1.
For details 
on AE collection and reporting, refer to the AE reporting information 
in Section 10.1.
Physical assessments are defined in below table:
Table 8
-4 Assessments and Specifications
Assessment Specification
Physical examination A complete physical examination will be 
performed at Screening and at Week 24 or 
premature discontinuation visit. It should include 
the examination of general appearance, skin, 
neck (including thyroid), eyes, ears, nose, throat, 
lungs, heart, abdomen, back, ly mph nodes, 
extremities, vascular, and neurological. If 
indicated based on medical hist ory and/or 
symptoms, rectal, external genitalia, breast, and 
pelvic exams will be performed.
Information for all physical examinations must be 
included in the source documentation at the 
study site. Clinically relevant findings that are 
present prior to si gning informed consent must 
be included in the Medical History part of the 
eCRF . Significant findings made after signing 
informed consent which meet the definition of an 
Adverse Event must be recorded on the Adverse 
Event section of the eCRF.
Vital signs Vital signs include blood pressure and pulse 
measurements. Vital signs are measured as per 
visit schedule indicated in Table 8-1.
After the subject has been sitting for 5minutes, 
with back supported and both feet placed on the 
floor, sy stolic and diastolic blood pressure will be 
measured 
3times using an automated validated 
device, e.g. OMRON, with an appropriately sized 
cuff. The repeat sitting measurements will be 
made at 1 - 2 minute intervals and the mean of 
the 3measurements will be used. In case the 
cuff sizes available are not large enough for the 
subject's arm circumference, a 
sphygmomanometer with an appropriately sized 
cuff may  be used.
Clinically notable vital signs are defined in 
Section 16.1 .

Novartis Confidential Page 68
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
Height and weight Body height in centimeters (cm) and body weight 
(to the nearest 0.1 kilogram (kg) in indoor 
clothing, but without shoes) will be measured at 
Screening. Body w eight will b e measured in 
addition at Week 24 or premature 
discontinuation visit.
8.4.1 Laboratory  evaluations
A central laboratory  will be used for analy sis of all specimens collected. Details on the 
collections, shipment of samples and reporting of results by the central laboratory are provided 
to investigators in the laboratory  manual. Laboratory  assessments wil l be performed in the visits 
specified in Table 8-1.
Clinically  significant abnormalities must be recorded as either medical history  or adverse events 
as appropriate. All patients with laboratory  tests containing clinically  significant abnormalities 
should be followed regularly until the values return to within the normal ranges or until a valid 
reason other than drug-
related adverse experiences is identified, even after the medication has 
discontinued. Clinically  notable labora tory values are defined in Section 16.1.
Table 8
-5 Laboratory  parameters
Test Category Test Name
Hematology Hematocrit, Hemoglobin, Platelet s, Red blood 
cells, W hite blood cells, Differential (Basophils, 
Eosinophils, Ly mphocytes, Monoc ytes, 
Neutrophils)
Clinical Chemistry For all visits:
Albumin, Alkaline phosphatase, alanine 
aminotransferase ( ALT),aspartate 
aminotransferase ( AST),Blood Urea Nitrogen 
(BUN), Calc ium, Creatinine, Gamma -
glutam yltransferase (GGT), Lactate 
dehy drogenase (LDH), Magnesium, 
Phosphorus, Potassium, Sodium, Total Bilirubin, 
If the total bilirubin concentration is increased 
above 1.5 times the upper limit of normal range, 
total bilirubin should be differentiated into the 
direct and indirect reacting bilirubin
At Day 1, W eek 12 and W eek 24/PSW  only:
HbA1c will also be measured
Urinalysis Microscopic Panel: Red Blood Cells, W hite 
Blood Cells, Cas ts, Cr ystals only if abnormalities 
on the macroscopic panel (dipstick) are 
detected.
Macroscopic Panel (Dipstick): Blood, pH, 
Protein, Specific Gravity
Coagulation Prothrombin time i nternational normalized ratio 
(PT/INR) at Run In 1 and at Week 24/PSW  only

Novartis Confidential Page 69
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
Pregnancy Test Serum /Urine pregnancy test for women of 
childbearing potential
Patient does not require fasting for the laborator y assessments
8.4.2 Electrocardiogram (ECG)
Triplicate ECGs (3ECGs are collected within about a five-minute window) must be recorded 
after 10 minutes rest in the supine position to ensure a stable baseline/according to the ECG 
investigator manual .The preferred sequence of cardiovascular data collection during study
visits is ECG collection first, followed by vital signs, and blood sampling. A minimum 3 
minutes rest period from the beginning of ECG assessments to the start of spirometry maneuvers 
must be observed at all times.
Where clinical decisions are based on the QT interval, the length of the QT interval is to be 
calculated according to the F ridericia QT correction formula (QTcF) . 
Triplicate ECGs are collected pre-dose and at 3 hours post-dose on Day 1, Day 15,andDay 
169 as indicated in Table 8-1.For patients participating in the optional additional PK sampling 
sub
-group, is should be 4 h post- dose on Day  1 and Day  15 instead of 3 hours post -dose.
Triplicate ECGs are collected at pre-dose at visits indicated in Table 8-1.All ECG s must be 12-
lead ECGs. For each ECG performed, original traces and identical duplicate traces should be 
printed. Each ECG will be sent electronicall y for central review directly  from the ECG machine. 
Two 'ident ical' duplicate print -outs will be generated and kept at the investigator site as source 
documentation and as back up for submission to the central laboratory in case of problems with 
the electronic transmission. Each print -out will be kept at the investig
ator site and will be dated 
and signed. The patient's number, the date, actual time of the tracing and study  code must appear 
on each page of the tracing. Clinically  significant abnormalities must be recorded on the eCRF 
as either medical history /current m edical conditions or adverse events as appropriate.
8.4.3 Pregnancy  and assessments of fertility
All pre-menopausal women who are not 
surgically  sterile (women of childbearing potential) 
will have pregnancy  testing. A serum or urine pregnancy  test will be perfor med (urine test kits 
provided to the sites by  the Central Laboratory /serum pregnancy  tests conducted by the Central 
Laboratory )as per assessment schedule Table 8-1. A positive pregnancy  test at any time during 
the study requir es the patient to be discontinued from the study  treatment. Refer to Section
9.1.1
for more details. Additional pregnancy  testing can be performed if required by local authorities.
8.5 Additional assessments
8.5.1 Pharmacokinetics
Blood samples will be obtained from all subjects as per visits and timepoints indicated in
Table 8-1and Table 8-2.
In approximately  48 subjects, additional PK samples at Day  1 and Day  15 will be collected, as 
per Table 8-3, to examine the time-concentration profiles of QBW251 after single dose and 
multiple doses in the COPD patients. Furthermore, additional PK samples will be collected, 

Novartis Confidential Page 72
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
Emergence of a SAE that the I nvestigator suspects to be related to investigational drug 
shall lead to immediate stop of investigational treatment. A blood sample to assess the 
exposure level should be taken, where possible, for expedited assessment. Where no blood 
sample at the time of occurrence of the SAE can be obtained, the last sample taken prior to 
the start of the SAE will be assessed.
Emergence of an AE that is of severe intensit y and that the I nvestigator suspects to be 
related to investigational drug shall lead to immediate stop of investigational treatment.
In case of emergence of a SAE that the Investigator does not suspect to be related to 
investigational drug, investigational treatment can be continued. A blood sample to assess 
the exposure level should be taken, where possible, for expedited assessment. I f the SAE 
coincided with a verified exp osure above the AUC threshold of AUC 0-24h= 91 700
ng×h/mL , investigational drug needs to be permanently
 stopped as soon as possible upon 
receipt of the PK results.
A patient with a verified exposure above the upper range of the individual animal 
(monkey ) model exposure (AUC 0-24h= 159 000 ng×h/mL ). The investigator must 
permanentl y discontinue the investigational drug as soon as possible upon receipt of the 
PK results.
Any laboratory  abnormalities that in the judgment of the investigator, taking into 
consi deration the subject’s overall status, prevents the subject from continuing 
participation in the study .
Any liver event requiring immediate discontinuation of study  treatment, as specified in 
Table 16
-2. 
In case of confirmed QTcF > 500 msec, as indicated in Section 6.5.1.1.
Investigational drug can be temporaril y interrupted as a response to the 
occurrence of adverse 
events that do not fulfil the requirements above described for permanent discontinuation (refer 
to Section 6.5.1).
If permanent discontinuation of investigational treatment occurs, the investigator should make 
a reasonable effort to understand the primary  reason for the 
subject’s premature discontinuation 
of investigational treatment and record this information. 
The investigator must also contact the IRT to registe r the subject’s discontinuation from 
investigational treatment.
If discontinuation occurs because treatment code has been broken, please refer to Emergenc y 
breaking of treatment code Section 6.6.2.
Subjects who have their 
investigational treatment permanently  discontinued should NOT be 
considered withdrawn from the study  UNLESS they withdraw their consent (see withdraw of 
informed consent section). Where possible, they should return for the assessments indicated 
in the assessment schedule in Table 8-1. If they fail to return for these assessments for unknown 
reasons, every  effort (e.g. telephone, e-mail, letter) should be made to contact the subject/pre -
designated contact as specified in the lost to follow -up section. This contact should preferably 
be done according to the study visit schedule. If the subject cannot or is unwilling to attend an y 
visit(s), the site staff should maintain regular telephone contact with the subject, or with a person 
pre-designated by the subject. This telephone contact should preferabl y be done according to 

Novartis Confidential Page 73
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
the study  visit schedule and at a minimum information on new/ concomitant treatments and 
adverse events /serious adverse events should be obtained.
9.1.1.1 Replacement poli cy
Discontinued patients will not be replaced on study.
9.1.2 Withdrawal of informed consent
Subjects may voluntarily  withdraw consent to participate in the study  for any reason at any time. 
Withdrawal of consent occurs onl y when a subject:
Does not want to part icipate in the study  anymore
and
Does not allow further collection of personal data.
In this situation, the investigator should make a reasonable effort (e.g. telephone, e -mail, letter) 
to understand the primary reason for the subject’s decision to withdra w his/her consent and 
record this information.
Study  treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing.
Further attempts to contact the subject are not allowed unless safety  findings require 
communicating or follow -up.
All efforts should be made to complete the assessments prior to study  withdrawal. A final 
evaluation at the time of the subject’s study  withdrawal should be made as detailed in the 
assessment table.
Novartis will continue to keep and use collected study  information (including any data resulting 
from the analysis of a subject's samples until the time of withdrawal) according to applicable 
law.
For US and Japan: all biological samples not yet analyzed at the time of withdrawal may still 
be used for further testing/analy sis in accordance with the terms of this protocol and of the 
informed consent form.
For EU and the rest of the world ( RoW ): all biological samples not yet analy zed at the time of 
withdrawal will no longer be used, unless permitted by applicable law. They  will be stored 
according to applicable legal requirements.
9.1.3 Lost to follow -up
For subjects whose status is unclear because they  fail to appear for study  visits without stati ng 
an intention to discontinue or withdraw, the investigator must show "due diligence" by 
documenting in the source documents steps taken to contact the subject, e.g. dates of telephone 
calls, registered letters, etc. A subject should not be considered as lost to follow -
up until due 
diligence has been completed.

Novartis Confidential Page 74
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
9.1.4 Early  study termination by  the sponsor
The study  can be terminated by  Novartis at any  time for any  reason. This may  include reasons 
related to the benefit/ risk assessment of participating in the st udy, practical reasons (including 
slow enrollment), or for regulatory  or medical reasons. Exposure driven termination rules are 
described below in Section 9.1.4.1. In taking the decision to terminate, Novartis will always
consider the subject welfare and safet y. Should early  termination be necessary , subjects must 
be seen as soon as possible. The Investigator should ensure contact is made as quickl y as 
possible by telephone and/or e
-mail and/or letter. If the study  is stopped for a change in the 
benefit/risk assessment or for medical reasons, patients may be instructed to stop taking the 
investigational drug QBW251 immediately . Else, patients may be instructed to continue 
QBW251 intake until they can return to the site for a final assessment. Background medication 
(LABA/LAMA/ICS) should be continued until the final visit. The patient should be treated as 
a prematurel y withdrawn subject and undergo all assessments of the premature withdrawal visit. 
The investigator may be informed of additional procedures to be followed in order to ensure 
that adequate consideration is given to the protection of the subject’s interests. The investigator 
or sponsor depending on the local regulation will be responsible for informing IRBs/IECs of
the earl y termination of the trial.
9.1.4.1 Criteria for premature termination of treatment arm(s)
As described in the risks and benefits section (Section
4.5), this protocol features a PK 
monitoring 
plan to ensure that patients' exposures are generall y consistent with an exposure 
threshold (AUC 0-24h=
91 700 ng×h/mL ), which was established based on animal (monkey ) data. 
Therefore, the cohort stopping rules have 
been developed to comply  with this goal. The 
independent Data Monitoring Committee (Section 10.2.3) will periodically  review the 
cumulating PK data against these rules.
The 2
rules described below support 2 aims:
-Limit the proportion of patients that exhibits exposures (AUC) above the threshold
-Limit the number of patients with exposures that are above the upper range of the exposures 
(AUC) observed in the animals.
Based on these goals, a treatment arm will be permanently  discontinued if:
1. 
At predefined safet y interim read outs the observed proportion of patients above the threshold 
(AUC 0-24h= 91 700 ng×h/mL ) is significant greater than expected. Statistical details of this rule 
are described in Section 12.7.1 .
and/or
2. More than one patient exhibi ts a projected AUC above the upper range of the individual 
animal (monkey ) exposures (AUC 0-24h = 159 000 ng×h/mL ). In case the 2 patients are in 
separate treatment arms, the treatment arm with the lowest dose will determine all the treatment 
arms to be pre maturel y terminated.
Any treatment arm* fulfilling either one of these criteria will lead to the permanent 
discontinuation of study  investigational drug for the patients in such treatment arm. New 
patients would be randomized to the remaining treatment arm s.

Novartis Confidential Page 75
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
PK exposure values above the threshold due to unverified sampling or analy sis or the 
consequence of an accidental/voluntary overdosing will not be included in the determination of 
whether to stop a treatment arm.
* The affected treatment arm with the lowest dose will determine which treatment arm(s) will 
be discontinued (all the ones above it). For instance if the stopping rules impact the 300 mg 
b.i.d. treatment arm (but not the 450 mg b.i.d. treatment arm) both the 300 mg and the 450 mg
arms will be di scontinued as described above.
9.2 Stud y completion and post -study  treatment
Study  completion is defined as when the last subject finishes his/her Follow -Up visit (study 
completion visit), and any  repeat assessments associated with this visit have been documen ted 
and followed -up appropriately  by the Investigator, or in the event of an early study termination 
decision, the date when the last patient completes his/her premature termination visit (see 
Section 9.1.4).
Upon completio n of a patient's participation in the study , he/she should be treated according to 
his/her individual needs. It is not planned to provide QBW251 to study  participants after the 
study  is completed due to the early stage of development. Since this study  is aPhase 2 study , 
the safet y profile of the drug has not yet been established to the extent considered adequate for 
a provision of QBW251 with less stringent safety  monitoring. Should there be patients with 
significant clinical benefit from QBW251 over appro ved treatment alternatives and the safet y 
profile allow for treatment outside of the study , Novartis will consider to continue provision of 
the investigational treatment to these patients. Should there be a request from an investigator to 
provide post-trial treatment to a patient with evidence of significant clinical benefit from the 
use of QBW251 over the use of approved treatments, and the safet y profile of the drug allow 
for treatment outside of the controlled environment of a study , Novartis will consid
er to 
continue providing the investigational treatment to this patient.
10 Safety  monitoring and reporting
10.1 Definition of adverse events and reporting requirements
10.1.1 Adverse events
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and 
unintended sign [including abnormal laboratory  findings], sy mptom or disease) in a subject or 
clinical investigation subject after providing written informed consent for participation in the 
study . Therefore, an AE may  or may  not be temporally  or causall y associated with the use of a 
medicinal (investigational) product. The investigator has the responsibility for managing the 
safet y of individual subject and identify ing adverse events. Novartis qualified medical 
personnel will be readily  available to advise on trial related medical questions or problems.
The occurrence of adverse events must be sought by non -directive questioning of the subject at 
each visit during the study. Adverse events also may be detected when they are volunteered b y 
the subject during or between visits or through physical examination findings, laboratory  test 
findings, or other assessments.

Novartis Confidential Page 76
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
Adverse events must be recorded in the Adverse Events eCRF under the signs, symptoms or 
diagnosis associated with them, accompanied by  the fo llowing information (as far as possible) 
(if the event is serious refer to Section 10.1.2):
1.The severit y grade:
a.mild: usually  transient in nature and generally  not interfering with normal activities
,
b.moderate: sufficientl y discomforting to interfere with normal activities ,
c.severe: prevents normal activities .
2.its relationship to the study  treatment. If the event is due to lack of efficacy or progression 
of underl ying illness (i.e. progression of the study  indication) the assessment of causalit y 
will usually  be ‘Not suspected’. The rationale for this guidance is that the sy mptoms of a 
lack of efficacy  or progression of underly ing illness are not caused by  the trial drug, they  
happen in spite of its administration and/or both lack of efficacy  and progression of 
underly ing disease can only  be evaluated meaningfull y by an anal ysis of cohorts, not on a 
single subject .
3.its duration (start and end dates) or if the event is ongoing, an outcome of not 
recovered/not resolved must be re ported.
4.whether it constitutes a SAE (see Section 10.1.2 for definition of SAE) and which 
seriousness criteria have been met .
5.action taken regarding with study  treatment.
All adverse events must be treated appropriatel y. Treatment may  include one or more of 
the following:
a.Dose not changed ,
b.Dose Reduced/increased ,
c.Drug interrupted/withdrawn.
6.its outcome 
a.not recovered/not resolved,
b.recovered/resolved,
c.recovering/resolving,
d. recovered/resolved with sequelae,
e.fatal, or 
f.unknown.
Conditions that were alread y present at the time of informed consent should be recorded in 
medical history  of the subject.
Adverse events (including lab abnormalities that constitute AEs) should be described using a 
diagnosis whenever possible, rather t han individual underly ing signs and s ymptoms.
Adverse event monitoring should be continued for at least 30 days following the last dose of 
study  treatment.
Once an adverse event is detected, it must be followed until its resolution or until it is judged to
be permanent (e.g. Continuing at the end of the clinical trial), and assessment must be made at 
each visit (or more frequently , if necessary ) of any changes in severity , the suspected 
relationship to the interventions required to treat it, and the outcome .

Novartis Confidential Page 77
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
Information about adverse drug reactions for the investigational drug can be found in the 
Investigator ’sBrochure (IB).
Abnormal laboratory  values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:
they induce clinical signs or sy mptoms
they are considered clinically  significant
they require therapy
Clinically  significant abnormal laboratory  values or test results must be identified through a 
review of values outside of normal ranges/clinically  notable ranges, significant changes from 
baseline or the previous visit, or values which are considered to b e non -typical in subjects with 
the underl ying disease. Alert ranges for laboratory and other test abnormalities are included in 
Section 16.1.
10.1.2 Serious adverse events
An SAE is defined as any adverse event (appearance of (orworsening of any pre-existing)
undesirable sign(s), symptom(s) or medical conditions(s)) ,which meets any one of the 
following criteria:
fatal
life-threatening
Life-threatening in the context of a SAE refers to a reaction in which the subject was at risk 
ofdeath at the time of the reaction; it does not refer to a reaction that hy pothetically  might 
have caused death if it were more severe (please refer to the ICH
-E2D Guidelines).
results in persistent or significant disability /incapacity
constitutes a congen ital anomaly /birth defect
requires inpatient hospitalization or prolongation of existing hospitalization, unless 
hospitalization is for: 
routine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition
elective or pre- planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent
social reasons and respite care in the absence of any  deterioration in the subject’s 
general con dition
treatment on an emergency  outpatient basis for an event not fulfilling any  of the 
definitions of a SAE given above and not resulting in hospital admission
is medically  significant, e.g. defined as an event that jeopardizes the subject or may  
require medical or surgical intervention to prevent one of the outcomes listed above
Medical and scientific judgment should be exercised in deciding whether other situations should 
be considered serious reactions, such as important medical events that might not be immediately 
life threatening or result in death or hospitalization but might jeopardize the subject or might 
require intervention to prevent one of the other outcomes listed above. Such events should be 
considered as “medicall y significant”. Examples of such 
events are intensive treatment in an 

Novartis Confidential Page 78
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
emergency  room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do 
not result in hospitalization or development of dependency  or abuse.
All malignant neoplasms will be assessed as serious under “medically  significant” if other 
seriousness criteria are not met
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
All reports of intentional misuse and abuse of the product are also considered serious adverse 
event irrespective if a clinical event has occurred.
Upon reporting of an SAE, the investigator should make every  attempt to bring the patient for 
an unscheduled visit to collect a PK blood sample at a minimum, unless a plan ned visit for this 
patient is occurring within a week time of the reported SAE.
10.1.3 SAE reporting
To ensure subject safet y, every  SAE, regardless of causalit y, occurring after the subject has 
provided informed consent and until 30 days following the last administration of study  
treatment if there are post-treatment Follow -Upvisits with no required procedures must be 
reported to Novartis safety  within 24 hours of learning of its occurrence. Detailed instructions 
regarding the submission process and requirements are to be found in the investigator folder 
provided to each site.
SAEs occurring after the subject has provided informed consent until the time the subject is 
deemed a screen failure or run -in failure must be reported to Novartis.
For randomized subjects, SAEs occurring after the subject has provided informed consent until 
30 day s after the subject has discontinued or stopped study  treatment (which usually  would be 
the time of the Follow -Up visit) must be reported to Novartis.
All follow -up information for the SAE including information on complications, progression of 
the initial SAE and recurrent episodes must be reported as follow -up to the original episode 
within 24 hours of the investigator receiving the follow -up information. An SAE occurring at a 
different time interval or otherwise considered completely  unrelated to a previously  reported 
one must be reported separatel y as a new event.
If the SAE is not previously documented in the Investigator’s Brochure or Package Insert (new 
occurrence) and is thoug ht to be related to the study treatment, a Novartis Chief Medical Office 
and Patient Safety ( CMO & PS ) department associate may urgentl y require further information 
from the investigator for health authorit y reporting. Novartis may need to issue an Investigator 
Notification (IN) to inform all investigators involved in any study  with the same study  treatment 
that this SAE has been reported.
Suspected Unexpected Serious Adverse Reactions (SUSARs) will be collected and reported to 
the competent authorities andrelevant ethics committees in accordance with EU Guidance 
2011/C 172/01 or as per national regulatory requirements in participating countries.
Any SAEs experienced after the 30 day period from the last treatment (usually  marked by the 
Follow -Up visit) should only be reported to Novartis Safety  if the investigator suspects a causal 
relationship to study  treatment.

Novartis Confidential Page 79
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
10.1.4 Pregnancy  reporting
To ensure subject safety, each pregnancy occurring after signing the informed consent must be 
reported to Novartis within 24 hours of learning of its occurrence. The pregnancy  should be 
followed up to determine outcome, including spontaneous or voluntary  termination, details of 
the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal 
and/or newborn complications.
Pregnancy  should be recorded and reported by the invest igator to the CMO&PS department. 
Pregnancy  follow -up should be recorded on the same form and should include an assessment 
of the possible relationship to the investigational study  drug andany pregnancy  outcome. An y 
SAE experienced during pregnancy  must be reported.
Follow up of pregnancies should be conducted as described below:
At expected date of delivery  (EDD) +1 month: Mandatory  to all pregnancy  cases; 
pregnancy outcome, and other clinicall y relevant pregnancy data or changes in data, 
should be collected.
At EDD +2 months: Mandatory  if no answer is obtained after request at EDD+1 month; 
same information as at EDD+1 month should be collected.
At EDD+3 months: Mandatory  for all cases of live birth/unknown outcome; status of the 
baby  3 months after delivery , any development issue or abnormality that would not be 
seen at birth
EDD+12 months: Mandatory  for all cases of live birth/unknown outcome; infant health 
status and development.
10.1.5 Reporting of study treatment errors including misuse/abuse
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, subject or 
consumer (EMA definition).
Misuse refers to situations where the medicinal product is intentionally  and inappropriatel y used 
not in accordance with the protocol.
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal product, 
which is accompanied b y harmful ph ysical or ps ychological effects.
Study  treatment errors and uses outside of what is foreseen in the protocol will be collected in 
the dose administration record (DAR) eCRF, irrespective of whether or not associated with an 
AE/SAE and reported to Safety  only if associated with an SAE. Misuse or abuse will be 
collected and reported in the safet y database irrespective of it being associated with an AE/SAE 
within 24 hours of I nvestigator’s awareness.
Table 10-1 Guidance for capturing the study  treatment errors including 
misuse/abuse
Treatment error type Document in Dose 
Administration (DA R) 
eCRF (Yes/No)Document in A E 
eCRFComplete SA E form
Uninten tional study 
treatment errorYes Only if associated with 
an AEOnly if associated with 
an SAE

Novartis Confidential Page 80
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
Treatment error type Document in Dose 
Administration (DA R) 
eCRF (Yes/No)Document in A E 
eCRFComplete SA E form
Misuse/Abuse Yes Yes Yes, even if not 
associated with a SAE
For more information on AE and SAE definition and reporting requirements, please see the, 
respective sections.
10.2 Additional Safety  Monitoring
10.2.1 Liver safety monitoring
To ensure subject safety  and enhance reliability  in determining the hepatotoxic potential of an 
investigational drug, a standardized process for identification, monitoring and evaluation of 
liver events has to be followed.
The following 2categories of abnormalities /adverse events have to be considered during the 
course of the stud y (irrespective of whether classified/reported as AE/SAE):
Liver laboratory  triggers, which will require repeated a ssessments of the abnormal 
laboratory  parameter
Liver events, which will require close observation, follow- up monitoring and completion 
of the respective eCRF pages as detailed in the CRF Completion Guidelines.
Please refer to Section 16.2 for complete definitions of liver laboratory  triggers and liver events.
Every  liver event defined in Table 16-1 should be followed up by the investigator or designated 
personnel 
at the trial site, as summarized below. Additional details on actions required in case 
of liver events are outlined in Table 16-2. Repeat liver chemistry  tests (ALT , AST, total 
bilirubin ( TBL ), PT/INR, alkaline phosphatase ( ALP )and GGT ) to confirm elevation.
These liver chemistry  repeats will be performed using the central laboratory. If results will 
not be available from the central laboratory , then the repeats can also be performed at a 
local laboratory  to monitor the safet y of t he subject. If a liver event is subsequently  
reported, an y local liver chemistry tests previously conducted that are associated with this 
event should have results reported on the local laboratory  eCRF page,
If the initial elevation is confirmed, close ob servation of the subject will be initiated, 
including consideration of treatment interruption if deemed appropriate.
Discontinuation of the investigational drug (refer to the Discontinuation of study  treatment 
section), if appropriate
Hospitalization of th e subject if appropriate
Causality  assessment of the liver event
An investigation of the liver event which needs to be followed until resolution. These 
investigations can include based on investigator’s discretion: serology  tests, imaging and 
pathology  assessments, hepatologist’s consultancy; obtaining more detailed history  of 
symptoms and prior or concurrent diseases, history  of concomitant drug use, exclusion of 
underly ing liver disease and imaging such as abdominal ultrasound
, computer tomograph y 
(CT) or magnetic resonance imaging ( MRI ), as appropriate.

Novartis Confidential Page 81
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
All follow -up information, and the procedures performed must be recorded as appropriate in 
the eCRF.
10.2.2 Renal safety  monitoring
Renal safet y monitoring for the investigational drug will be performed in the study. This 
includes baseline measurements of serum creatinine, calcium, potassium and urine dipstick and 
at subsequent visits as indicated in the Schedule of Assessments Table 8-1and Laboratory 
parameters in Table 8-5.
10.2.3 Data Monitoring Committee
This study  will include a data monitoring committee (DMC) which will function independentl y 
of all other individuals associated with the conduct of this clinical trial, including the 
site 
investigators partici pating in the study . The DMC will assess at defined intervals the progress 
of a clinical trial, safet y data, and critical efficacy  variables and recommend to the sponsor 
whether to continue, modify  or terminate a trial. The DMC will furthermore assess at defined 
intervals the 
accumulating PK data and review these against the stopping rules (Section 9.1.4.1).
Specific details regarding composition, responsibilities, data monitoring and meeting frequency , 
and documentation of DMC reports, minutes, and recommendations will be described in a 
separate charter that is established between the sponsor and the DMC.
11 Data Collection and Database management
11.1 Data collection
Designated investigator staff will enter the data required by the protocol into the eCRF. The 
eCRFs have been built using fully validated secure web-enabled software that conforms to 21 
Code of Federal Regulations (CFR )Part 11 requirements, Investigator site staff will not be 
given access to the Electronic Data Capture (EDC
)system until they have been trained. 
Automatic validation programs check for data discrepancies in the eCRFs, allow modification 
and/or verification of the entered data b y the investig ator staff.
The investigator/designee is responsible for assuring that the data entered into eCRF is complete, 
accurate, and that entry  and updates are performed in a timely  manner. The Investigator must 
certify  that the data entered are complete and accur ate
After final database lock, the investigator will receive copies of the subject data for archiving 
at the investigational site.
All data should be recorded, handled and stored in a way that allows its accurate reporting, 
interpretation and verification.
11.2 Database management and quality  control
Novartis personnel (or designated Commercial Research Organization ( CRO )) will review the 
data entered by investigational staff for completeness and accuracy . Electronic data queries 
stating the nature of the proble m and requesting clarification will be created for discrepancies 
and missing values and sent to the investigational site via the EDC system. Designated 

Novartis Confidential Page 82
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
investigator site staff are required to respond promptly  to queries and to make any necessary 
changes to the data.
Concomitant treatments and prior medications entered into the database will be coded using the 
World Health Organization (WHO )Drug Reference List, which employ s the Anatomical 
Therapeutic Chemical classification system. Medical history /current medical conditions and 
adverse events will be coded using the Medical dictionary  for regulatory  activities (MedDRA) 
terminology .
Randomization codes and data about all study  treatment (s) dispensed to the subject and all 
dosage changes will be tracked using an Interactive Response Technology (IRT). The system 
will be supplied by a  vendor, who will also manage the database. The data will be sent 
electronically  to Novartis (or a designated CRO) at specific timelines.
Each occurrence of a code break via I RT wi ll be reported to the clinical team and monitor. The 
code break functionality  will remain available until study  shut down or upon request of Novartis.
Once all the necessary  actions have been completed and the database has been declared to be 
complete and accurate, it will be locked and the treatment codes will be unblinded and made 
available for data analysis.Any changes to the database after that time can only be made after 
written agreement b y Novartis development management.
11.3 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, a Novartis/ 
representative will review the protocol and data capture requirements (i.e. eSource Direct Data 
Entry  (DDE )or eCRFs) with the investigators and their staff. During the study , Novartis 
employ s several methods of ensuring protocol and GCP compliance and the quality /integrity  of 
the sites’ data. The field monitor will visit the site to check the completeness of subject records, 
the accuracy  of data capture /data entry, the adherence to the protocol and to Good Clinical 
Practice, the progress of enrollment, and to ensure that study  treatment is being stored, 
dispensed, and accounted for according to specifications. Key study personnel must be available 
to assist the field monitor during these visits. Continuous remote monitoring of each site’s data 
may be performed by a centralized Novartis Clinical Research Associate (CRA )organization. 
Additionally , a central analy tics organization may analyze data & identify  risks & trends for 
site operational parameters, and provide reports to Novartis clinical teams to assist with trial 
oversight.
The investigator must maintain source documents for each subject in the study , consisting of 
case and visit notes (hospital or clinic medical records) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information on eCRFs must be traceable to these source documents in the 
subject’s file. The investig ator must also keep the original informed consent form signed by the 
subject (a signed cop y is given to the subject).
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency  with the data capture and/or d ata entry . Novartis monitoring standards require full 
verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, 
documentation of SAEs, and of data that will be used for all primary  variables. Additional 
checks of theconsistency  of the source data with the eCRFs are performed according to the 

Novartis Confidential Page 83
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
study -specific monitoring plan. No information in source documents about the identity  of the 
subjects will be disclosed.
12 Data analy sis and statistical methods
Any data analy sis carried out independently  by the investigator should be submitted to Novartis 
before publication or presentation.
If not stated otherwise, all inferential analyses will not include the 450 mg dose due to early 
termination of the 450 mgb.i.d arm,resulting in very few or no data in some of the strata 
(covariates/factors in the model) during the later visits . All d escriptive summa ries will include 
the 450 mg b.i.d. dose .
12.1 Analysis sets
The Randomized Analy sis Set (RAS) consists of all randomized patients. Patients will be 
analyzed according to the treatment they  were assigned to at randomization. 
The Full Anal ysis Set (FAS) will include all randomized patients who received at least one dose 
of randomized treatment. Following the intent -to-treat principle, patients will be analy zed 
according to the treatment they were assigned to at randomization. It is reasonable to require 
that patients took randomized treatment for inclusion in the FAS because the decision on 
whether or not randomized treatment is started will not be influenced by the treatment group 
assignment due to effective treatment blinding procedures. 
The Safet y Set will include all patients who received at least one dose of double -blind treatment. 
Patients will be analy zed according to the treatment t hey received. 
Note that the FAS and Safet y Set are the same except that the Safety Set allows the inclusion 
of non-randomized patients who receive double -blind treatment in error. In addition, analy ses 
based on the FAS assigns randomized treatment while a nalyses based on the Safety Set assigns 
received treatment.
The PK set will include all patients with at least one evaluable drug concentration data sample. 
The PK serial sub
-group will include all patients with at least one evaluable drug concentration 
data sample and who consented to participate in the PK serial sub-group . Patients will be 
analyzed according to the treatment received for both sets.
12.2 Subject demographics and other baseline characteristics
Demographic and other baseline data, including disea se characteristics and relevant medical 
histories/current medical conditions , will be summarized de scriptivel y by treatment group.
12.3 Treatments
The duration of exposure in days to each treatment group (QBW251 dose or placebo) will be 
summarized by means of descriptive statistics. The following summaries for COPD -related 
medications will be performed separatel y for medications prior to run -in (medications starting 
prior to screening 
and ending prior to or at the run-in visit) and for concomitant medications 
(medications which were taken anytime between the first dose and last dose of randomized 
treatment, inclusive). COPD -related medications will be summarized by pre-specified drug 

Novartis Confidential Page 84
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
categories, route of administration, preferred term, and treatment group. Non-COPD related 
medication prior to and after the start of randomized treatment will be summarized by  route of 
administration, preferred term, and treatment group.
The number of patients who permanentl y discontinued from double blind treatment and the 
reasons w ill be summarized by  treatment group.
12.4 Analysis of the primary  endpoint(s)
The primary  objective of this study  is to characterize the DR (dose-response ) efficacy 
relationship among QBW251 doses (25, 75, 150 and 300mg b.i.d. ) and placebo with regards to 
the change from baseline in trough FEV 1after 12 weeks of treatment. The goals associated with 
this objective are below.
To confirm an overall DR signal
To estimate the dose(s) that corresponds to the target effect over placebo based on the 
estimated DR curve
12.4.1 Definition of primary  endpoint(s)
The primary  estimand, defined below, quantifies a hypothetical on-treatment Week 12 effect 
during stable periods (i.e. outside episodes of COPD worsening that require rescue medication 
or systemic corticosteroids). This es
timand targets the maximum treatment effect for QBW251 
and allows selection of the best dose for those who take it for 12 weeks.
Population : patients with moderate to severe COPD enriched for presence of chronic 
bronchitis and a history  of exacerbations and treated with LABA/LAMA/ICS background 
therap y
Variable : trough FEV 1(average of the 2values taken 15 and 45 min pre -dose) change 
from baseline after 12 weeks of treatment
Intervention effect of interest : Effect of interventions initiated at randomization during 
stable periods (i.e. outside episodes of COPD worsening that require rescue medication or 
systemic corticosteroids) and that would have been observed had all patients remained on 
their assigned treatment for 12 weeks, with the following post- rando mization events 
accounted for b y assessing: 
Intake of rescue medication or sy stemic corticosteroids (SCS): the effect outside of 
periods of worsening disease that necessitate rescue medication or SCS
Discontinuation of study  treatment or study  participation: hy pothetical on -treatment 
trough FEV 1value.
Missing data due to an y reason prior to completion or discontinuation of treatment: 
on-treatment trough FEV 1values.
Summary measure : mean difference be tween treatment groups (QBW251 compared with 
placebo)
The baseline value is defined as the average of the FEV 1values taken approximately  45 and 15 
minutes prior to first dose of randomized treatment at Day 1. If one of the 2values is missing 
(or is not c onfirmed to be pre -dose) then the remaining non -missing value will be taken as the 
baseline. If both values are missing (or are not confirmed to be pre-dose), then the 
measurements taken at the Run-In 1visit will be used as the baseline.

Novartis Confidential Page 85
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
12.4.2 Statistical model , hypothesis, and method of analy sis
The Multiple Comparison Procedure –Modelling (MCP -Mod) methodology  (see 
Bretz et al 2005 and Pinheiro et al 2014) will be employ ed to assess the primary  objective. An 
overview of the steps for the MCP -Mod methodology  is given below. Further details will be 
provided in the Statistical Analy sis Plan (SAP).
Step 1 (Testing an overall dose -response signal 
-MCP part):
The (covariate) adjusted mean responses at each individual dose will be obtained from a mixed -
effect linear model for repeated measures (MMRM) with terms for baseline FEV 1, visit, region, 
treatment, smoking status at screening, severity  of airflow limitation, treatment -by-visit 
interaction, run-in post-bronchodilator FEV1, and baseline FEV 1-by-visit interaction as fixed 
effects. To allow adjustment for correlations between timepoint s within patients, an 
unstructured variance
-covariance structure will be used.
The adjusted treatment means from the MMRM will be used to test the null hypothesis of a flat 
DR relationship for the primary  efficacy  endpoint at a one-sided significa nce level of 5% against 
the alternative hypothesis of a non-constant DR curve. The testing will be performed with a 
multiple contrast test described in the MCP -Mod methodology .
A wide range of possible dose-response relationship will be considered to take model 
uncertaint y into account (Figure 12
-1). A monotonic DR is assumed, supported by preclinical 
data and the observed DR of another CFTR -potentiator, ivacaftor. Eleven candidate DR curves 
(4 Emax, 4 
Sigmoid Emax, 2 Exponent ial, and 1 Linear) will be used to derive the optimal 
model contrasts for the multiple contrast tests. Emax and sigmoidal Emax models are 
considered based on the observed DR of ivacaftor (FDA 2012 ). The ED50 values (thedose at 
which half of the maximum effect is reached) for the Emax models will be 25, 75, 150, and 300. 
The parameters of the sigmoidal Emax models (ED50, h) will be (25, 3), (75, 3), (150, 3) and 
(300, 3) where h is the Hill parameter that determines the steepness of the dose -response shape. 
Exponential models are considered since there is an over -proportional increase of exposures at 
the high end of the dose range tested. The parameter controlling the convexity  of the 
Exponential models will be 150 and 30 0.
For each of the 11 candidate DR curves, a contrast test statistic will be derived that maximizes 
the power assuming the true mean response is the one assumed b y the candidate DR curve. The 
detection of a significant DR signal is based on the maximum of the 11 contrast test statistics. 
The overall null hypothesis of no DR relationship is rejected if the multiplicity  adjusted p-value 
for at least one contrast test is 
<0.05 (one sided).

Novartis Confidential Page 86
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
Figure 12-1 Candidate Dose Response Curves
Step 2 (Estimation of the dose- response curve and target dose –Mod part):

Novartis Confidential Page 87
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
Once the DR signal is declared, the DR curve and the target dose(s) of interest will be estimated 
by model averaging. A large number of bootstrap samples from the multivariate normal 
distribution will be drawn with adjusted means from the MMRM and corresponding covariance 
matrix. For each sample:
DR models from the candidate families (Emax, Sigmoid Emax, Exponential, Linear) will 
be fitted to the data and the best model according to the generalized Akaike information 
criterion (AIC)will be chosen.
The predictions for dose-response will be obtained from the best model.
The final DR curve estimate is the median of these predictions while confidence intervals will 
be calculated from the quantiles. The final DR curve estimate with the model -based two -sided 
90% confidence interval will be presented graphically . In addition, the plot will include the 
mean responses from the MMRM and the associated 90% confidence intervals for each of the 
studied dose groups.
The target dose(s) that corresponds to a clinically relevant effect over placebo can be estimated 
using inverse regression techniques (Bretz et al 2005 ). All data related to safet y, efficacy  and 
other assessments including PK exposure will be taken into consideration to propose a dose for 
Phase 3.
12.4.3 Handling of missing values/censoring/discontinuations
Since the estimand is related to an effect outside of rescue med intake, spirometry  measurements 
within 6 hours of rescue medication or within 7 days of intake of SCS use will be set to missing.. 
If one of the values contributing to the trough FEV 1variable is missing at a visit, the remaini ng 
non-missing value will be taken as trough FEV 1. If both values are missing, then their trough 
FEV 1will be regarded as missing at that visit.
For the primary  analysis, only on-treatment data (from date of first randomized dose up to 1 
day after date of last randomized dose) will be used as the estimand specifies a hypothetical on-
treatment effect. Missing on -treatment data will not be explicitly  imputed as the MMRM model 
implicitly  imputes missing data assuming the missing at random (MAR) mechanism.
The imputation procedure(s) related to the trough FEV 1supportive analyses (Section
12.4.4) 
are "jump -to-reference" (J2R) and MAR (Carpenter et
al2013). The imputations will be based 
on al
l available data (i.e. from all scheduled timepoint s) using all covariates as specified in the 
MMRM. For J2R, only placebo (reference) data will be used. For MAR, data from the same 
treatment arm will be used for building the imputation model. Imputation of intermittent 
missing observations before treatment discontinuation will be carried out following a MAR 
mechanism for all treatment arms. Additional details will be available in the SAP.
12.4.4 Supportive analy ses
A supplementary  analysis will be performed 
that quantifies the treatment effect in all 
randomized patients during stable periods (i.e. outside episodes of COPD worsening that 
require rescue medication or SCS) with an adherence to treatment like we would see in clinical 
practice in a world without COVI D-19, with the following post-randomization events 
accounted for b y assessing:

Novartis Confidential Page 88
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
a.Intake of rescue medication or sy stemic corticosteroid: effect outside of periods of 
worsening disease that necessitate rescue med or sy stemic corticosteroid
b.Discontinuation of study  treatment for non-COVID -19 reason with follow -up: actual off -
treatment value. If no data was retrieved after study treatment discontinuation, missing 
data will be multiply  imputed based on placebo arm data: J2R assumption for the 
Q
BW251 arms and MAR assumption for placebo arm.
c.Discontinuation of study  treatment due to a COVID -19 related reason: on -treatment value. 
Missing data will be multiply  imputed based on the MAR assumption. 
d.Discontinuation of study  participation due to any  non-COVID - 19 related reason: off-
treatment value. Missing data will be multiply  imputed based on placebo arm data: J2R 
assumption for the QBW251 arms and MAR assumption for placebo arm.
e.Any other event leading to missing data prior to completion or discont inuation of study  
treatment: on -treatment value. Missing data will be multiply  imputed based on the MAR 
assumption.
Additional sensitivity  and/or supportive analyses may also be added to explore the impact of 
COVID -19 in the SAP.
A supportive exposure- response anal ysis may  also be performed.
12.5 Analysis of secondary  endpoints
No multiplicity  adjustment will be carried out for secondary  analyses described below. In 
addition, the treatment effect of QBW251 compared to placebo that would have been observed 
had all patients remained on their assigned treatment will be estimated. Only  data obtained 
while patient is on-treatment (from date of first randomized dose up to 1 day after date of last 
randomized dose) will be used. Missing data for any  reason will not be e xplicitly  imputed and 
will be handled by the respective mixed effects model which implicitly  imputes missing data 
assuming MAR.
12.5.1 Efficacy  and/or Pharmacody namic endpoint(s)
12.5.1.1 COPD sy mptoms
12.5.1.1.1 Respiratory symptoms from E -RS
The E-RS assesses both overall daily respiratory  COPD symptoms (Total score) and specific 
respiratory  symptoms using 3subscales (Breathlessness, Cough & Sputum, and Chest 
Symptoms). Higher scores indicate more severe sy mptoms.
The mean baseline E-RS Total and subscale scores will be the averag e of the corresponding 
daily  scores from the run-in period. The last 14 days of the run-in period , i.e. the scheduled 
duration of run -in period, will be considered. A patient needs to have at least 8 days of data 
from the run-in period in order for the mea n baseline score to be calculated.
The daily scores post -randomization will be averaged for each week (Week 1, Week 2, etc.). A 
patient needs to have at least 4 days of data in any week in order for the mean score to be 
calculated.

Novartis Confidential Page 89
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
Monthly  means over a 4- week period will also be calculated. A patient needs to have at least 3 
weekl y means in that month in order for the monthly  mean score to be calculated.
E-RS Cough & Sputum score
The change from baseline in the E-RSWeek 12Cough & Sputum mean scores willbe analy zed 
using the same MCP -Mod approach described in Section 12.4 for the primary  analysis of the 
primary  variable. The change from baseline in the E -RS Cough & Sputum weekl y mean scores
will be analyzed using a simila r MMRM as described in Section 12.4 for the primary variable, 
with the appropriate baseline score replacing the baseline FEV 1value in the model. The 
estimated treatment difference (QBW251 –placebo) at each week will be reported along with 
the associated 90% confidence interval.
The proportion of patients who achieve a clinically  important improvement (decrease) of at 
least 0.7 ( Leidy et al 2014b)in the weekl y mean score will be analyzed using a repeated 
measurements logistic regression. The model will include the same terms as for the MMRM 
analysis of the weekly scores. The estimated odds ratios will be display ed over time along with 
the associated 90% confidence intervals.
The c hange from baseline in the monthly mean scores will be analyzed using a similar MMRM 
as described above. The proportion of patients who achieve a clinically important improvement 
(decrease) in the monthly mean score will also be anal yzed as described above .
E
-RS Total, Breathlessness, and Chest Symptoms scores
The change from baseline in the E-RS weekly  mean Total, Breathlessness, and Chest Symptom 
scores will be analyzed using a similar MMRM as described in Section 12.4 forthe primary 
variable with the appropriate baseline E
-RS score replacing the baseline FEV 1value. The 
estimated treatment difference (QBW251 –placebo) will be reported along with the associated 
90% confidence interval.
The minimum clinically  important improvements (decrease) for the scores are defined below 
(Leidyet al 2014b).
Total ≥ 2.0
Breathlessness ≥ 1.0
Chest Sy mptoms ≥ 0.70
The proportion of patients who achieve a clinicall y important improvement in the weekl y mean 
scores will be analyzed using a repeated measurements logistic regression. The model will 
include the same terms as for the MMRM analysis of the weekl y mean scores. The estimated 
odds ratios will be displayed over time along with the associated 90% co nfidence intervals.
The change from baseline in the monthly mean scores will be analyzed using a similar MMRM 
as described above. The proportion of patients who achieve a clinically important improvement 
(decrease) in the monthly mean score will also be an alyzed as described above.
12.5.1.1.2 Cough and sputum symptoms from CASA -
Q
CASA -Q assesses cough and sputum sy mptoms and their impact with 4 domain scores (cough 
symptoms, cough impact, sputum symptoms, and sputum impact). The change from baseline in 
the domain scores will be analyzed using the MMRM described inSection 12.4 for the primary 

Novartis Confidential Page 90
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
variable with the appropriate baseline domain score replacing the baseline FEV 1value in the 
model. The estimated treatment difference (QBW251 – placebo) at each visit will be reported 
along with the associated 90% confidence interval.
12.5.1.1.3 Severity of symptoms from PGI-S
The PGI -S rates the severity  of the respiratory  symptoms and of cough and mucus. Shift tables 
will be used to compare baseline to Weeks 12 and 24 for each PGI-S value. The proportional 
odds model for repeated measures with the same terms as for the MMRM analysis described in 
Section 12.4 for the primary  variable with the baseline PGI-S value replacing the baseline FEV 1
value. The estimated odds ratios will be display ed over time along with the associated 90% 
confidence intervals.
12.5.1.2 Health -related quality of life from SGRQ
SGRQ measures health impairment. A total score is produced, along with the domain scores of 
symptoms, activity , and impacts. The Weeks 12 and 24 change from baseline in the SGRQ total 
and domain scores will be analyzed using the MMRM described in Section 12.4 for the primary 
variable with the appropriate baseline SGRQ score 
replacing the baseline FEV 1value in the 
model. The estimated treatment difference (QBW251 –placebo) at each visit will be reported 
along with the associated 90% confidence interval.
The proportion of patients who achieve a clinically  important improvement (decrease) of at 
least 4 in the total score will be analy zed using a repeated measurements logistic regression. 
The model will include the same terms as for the MMRM analy sis of the total scores. The 
estimated odds ratios will be display ed over time along with the associated 90% confidence 
intervals.
12.5.1.3 Lung function
The change from baseline in trough FEV 1at visits other than Week 12 will be analyzed using 
the same MMRM as described in Section
12.4 for the primary anal ysis of the primary variable. 
The estimated treatment difference (QBW251 –placebo) at each visit will be reported along 
with the associated 90% confidence interval. The change from baseline in trough FEV 1at Week 
24 will also be anal yzed using the same MCP -Mod approach described in Section 12.4.
The change from baseline in trough FVC after 4, 8, 12, 16, 20, and 24 weeks of treatment will 
be analyzed using the MMRM model described in Section
12.4 for the primary  variable. The 
estimated treatment difference (QBW251 –placebo) at each visit will be reported along with 
the associated 90% confidence interval.
12.5.2 Safety  endpoints
Safety  summar ies include only data from the on-treatment period with the exception of baseline 
data which will also be summarized where appropriate (e.g. change from baseline summaries).
Adverse events
The on-treatment period for adverse events lasts from the date of first administration of double -
blind study  treatment to 30 days after the date of the last actual administration of randomized 

Novartis Confidential Page 91
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
study  treatment. Adverse events will be summarized by treatment group. Summary  tables for 
AEs will summarize only  on-treatment eve nts (also known as treatment -emergent AEs).
The number (and percentage) of subjects with treatment -
emergent adverse events will be 
summarized in the following way s:
by treatment, primary  system organ class and preferred term.
by treatment, primary  system organ class, preferred term and maximum severity .
Separate summaries will be provided for study  medication related adverse events, death, serious 
adverse events and other significant adverse events leading to discontinuation.
A subject with multiple adverse events within a primary  system organ class or preferred term 
is only  counted once towards the total of the primary  system organ class or preferred term.
In addition ,treatment emergent AEs and SAEs will be presented by treatment, system organ 
class and preferred term, showing exposure adjusted event rates (i.e., the number of events 
expressed in rates per 100 patient year s).
Vital signs
The on-treatment period for vital signs will be defined in the SAP. Summary  statistics will be 
provided by treatment and visit/time for each vital signs variable. Notable values (to be defined 
in the SAP) and change from baseline will also be summarized. The baseline value is the last 
value prior to first dose of double -blind treatment.
12
-lead ECG
The on-treatment period for ECG will be defined in the SAP. Summary  statistics will be 
provided by treatment and visit/time for each ECG variable. Categorical analy sis of QTc 
interval data based on the number of subjects meeting or exceeding predefined lim
its (to be 
defined in the SAP) in terms of absolute QTc intervals or changes from baseline will be 
presented. The baseline value is the last value prior to first dose of double -blind treatment.
Clinical laboratory  evaluations
The on-treatment period for labs will be defined in the SAP. Summary  statistics will be 
provided b y treatment and visit/time by  each lab variable.
For selected laboratory  tests, the number and percentage of patients with newly  occurring or 
worsening laboratory  abnormalities meeting t
he clinically  notable criteria (to be defined in the 
SAP) will be summarized by laboratory  parameter. Change from baseline will also be 
summarized. The baseline value is the last value prior to first dose of double -blind treatment.
12.5.3 Pharmacokinetics
Descrip tive summary  statistics of QBW251B plasma concentration data will be provided by 
treatment and visit/sampling timepoint , including the frequency (n, %) of concentrations below 
the lower limit of quantification (LLOQ). Summary  statistics will include mean (arithmetic and 
geometric), standard deviation, coefficient of variation (arithmetic and geometric), median, 

Novartis Confidential Page 93
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
12.7 Interim analy ses
12.7.1 Safety
IAs are planned for the monitoring of PK and safety  data and do not inflate the ty pe I error for 
the primary  efficacy  hypothesis testing. Thus no adjustment for multiplicity  is re quired. These 
analyses will be performed by an external Independent Statistician and an Independent 
Programmer for an independent external safety DMC. Persons directly involved in the conduct 
of the clinical trial will not be involved in performing the IA or reviewing the results. The DMC 
will be provided with reports which are semi -blinded. If necessary , the study  treatment can be 
unblinded by the chair of the DMC. The DMC will review PK and safety  data and make 
recommendations regarding the conduct of thetrial and/or alteration of the current protocol, 
including termination of a treatment arm. As mentioned inSection 9.1.4.1, a treatment arm 
(along with all other treatment arms with higher doses administered) will be terminated if the 
observed proportion of patients above the exposure threshold (AUC 0
-24h = 91 700 ng×h/mL ) is 
significant greater than expected. It is expected that < 5% of patients 
on 300 mg or 450 mg b.i.d.
will exceed the threshold based on a conservative scenario. An α-spending function with Pocock 
type stopping boundary  (as implemented in East 6.4) will be used to construct the stopping 
boundaries (Lan et al 1983) using the p-value scale such that the overall significa nce level 
across all analyses is maintained at 0.05. 
At each interim analysis, an exact test on the proportion 
of subjects who exceed the exposure threshold will be performed to test the following 
hypotheses for these 2 treatment arms.
Null hy pothesis (Ho) : the proportion of patients exceeding the exposure threshold < 5% 
Alternative h ypothesis (Ha): the proportion of patients exceeding the exposure threshold 
≥5% 
The interim anal yses are proposed to occur when 20%, 40%, 60%, 80%, and 100% of subjects 
have completed at least 4 weeks of treatment, which should be long enough to determine if the 
patient's exposure will exceed the threshold or not. The corresponding stopping boundaries in 
the p-value scale are 0.015, 0.016, 0.017, 0.018, and 0.019 for the interim analy ses.For example, 
when the first interim analy sis is performed after 20% patients have completed 4 weeks of 
treatment in the 450mg b.i.d. arm, the observed (i.e. nominal) p- value has to be equal to or 
smaller than 0.015 in order to reject Ho and terminate the treatment arm. 
If the true proportion of patients in the 300 mg or 450 mg b.i.d. treatment arm exceeding the 
exposure threshold is < 5%, then the probability  of rejecting Ho would be very low (<5%) with 
this group sequential testfor the treatment arm. If the true proportion is 10% then the probability 
of rejecting Ho and stopping the treatment arm early  would be high (
≥77%). If the timing of the 
actual interim analy ses deviate from the proposed schedule (20%, 40%, 60%, 80%, and 100% 
completed at least 4 weeks of treatment), stopping boundaries will need to be recalculated using 
the pre-specified α- spending function and based on the actual sample size at each interim 
analysis. The observed p- values at the interim analy ses will then be compared against the re-
calculated stopping boundaries.
After reviewing the exposure data from the first interim analy sis, the DMC informed the 
sponsor that the 450 mg b.i.d. arm had crossed the stopping boundary and recommended 
termination of the treatme nt arm. The DMC confirmed that the arm was well tolerated in this 
patient population and the stop was not based on adverse reactions to the 450 mg b.i.d. regimen.   

Novartis Confidential Page 94
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
The sponsor followed the DMC’s advice and discontinued investigational treatment from all 
patients randomized to the 450 mg b.i.d. arm.  
More detailed criteria will be outlined in the DMC charter .
12.7.2 Efficacy
Up to 2 IAs on efficacy  data may  be conducted and the timing will correspond to 1 or 2 safety 
DMC analyses. The purpose of these IA(s) is to have 
an early assessment of the data for 
planning future studies in the QBW251B program. The efficacy  IA results will not trigger any 
change or decision in the conduct of this study .
An internal Novartis committee, external to the study  team, will be set up to review the both the 
efficacy  and 
safet y data. Once team members are exposed to the unblinded IA data, they will 
no longer be involved in the further execution of the study . A charter will provide further details.
The first IA will be conducted when approximately  645 to 680 patients, including ~102 patients 
randomized to the 450 mg b.i.d. arm, have either discontinued or completed 12 weeks of 
treatment. This I A will have acceptable precision for the estimated trough FEV 1dose-response
curve. The average half-length of the 90% confidence interval is around 2 6mL and 32 mL for 
the estimated dose-response curve and the estimated placebo -adjusted dose-response curve, 
respectivel y.If the first IA does not lead to a clear decision for the planning of the QBW2 51B 
program, a second IA may be performed when all randomized patients have either discontinued 
or completed 12 weeks of treatment.
12.8 Sample size calculation
A total of 956 patients will be randomized to one of the 6 groups including 5 QBW251 dose 
groups (450, 300, 150, 75, 25 mg b.i.d.) and placebo. This includes the ~102 patients 
randomized to the 450 mg b.i.d. a rm prior to its discontinuation. Prior to the discontinuation of 
450mg b.i.d., patients were randomized to QBW251 450, 300, 150, 75, 25 mg b.i.d., or placebo 
with an allocation ratio of 2:2:1:1:1:2. After discontinuation of 450mg b.i.d., patients were 
randomized to QBW251 300, 150, 75, 25 mg b.i.d., or placebo with anallocation ratio of 
2:1:1:1:2. This sample size of 854 (956 total minus approximately  102 patients alread y 
randomized to 450 mg b.i.d.) achieves at least 80% power for dose-response signal detection 
on key endpoints for all models from the candidate set based on the MCP -Mod methodology 
and also to ensure an acceptable precisio n for the DR curve estimation. The calculations in 
Table 12-1 exclude 450 mg b.i.d. from the anal ysis and are based on a 20% dropout rate, a one -
sided significance level of 5%, and the following standard deviation assumptions.
Pre-dose trough FEV 1: A common standard deviation of 200 mL  based on previous 
Novartis COPD studies.
E
-RS Cough & Sputum weekl y mean score: A common standard deviation of 1.3 based on 
the FLAME study  (Wedzicha et al 2016) .
Table 12
-1 Power and Precision
Variable Power to detect a 
DR signalAverage half -length of 90% 
confidence interval

Novartis Confidential Page 95
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
Maximum 
improvement 
over placeboEstimated DR 
curveEstimated 
placebo -adjusted 
DR curve
Trough FEV 1 60 mL
50 mL92%
81%21 mL 26mL
E-RS Cough & 
Sputum0.35
0.3086%
76%0.14 0.17
Power calculations were performed using ADDPLAN -DF-4.0 and the precision estimates (half -length 
of confidence interval) were obtained from simulations.
The randomization ratio was based generall y on D-optimality  criteria, which maximize the 
information on the dose response curve ,forthe MCP -Mod anal ysis.The D -optimal allocation 
ratio randomizes approximately twice as many patients to placebo and the highest dose, 
compared to the middle doses.  
13 Ethical considerations and administrative procedures
13.1 Regulatory  and ethical compliance
This clinical study  was designed and shall be implemented, executed and reported in accordance 
with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable 
local regulations (including European Directive 2001/20/EC, US CFR 21), and with the ethical 
principles laid down in the Declaration of Helsinki.
13.2 Responsib ilities of the investigator and IRB/IEC
Before initiating a trial, the investigator/institution must obtain approval/favorable opinion from 
the Institutional Review Board/Independent Ethics Committee (I RB/IEC) for the trial protocol, 
written informed conse nt form, consent form updates, subject recruitment procedures (e.g.
advertisements) and any other written information to be provided to subjects. Prior to study 
start, the investigator is required to sign a protocol signature page confirming his/her agreem ent 
to conduct the study  in accordance with these documents and all of the instructions and 
procedures found in this protocol and to give access to all relevant data and records to Novartis 
monitors, auditors, Novartis Quality  Assurance representatives, de signated agents of Novartis, 
IRBs/IECs, and regulatory  authorities as required. If an inspection of the clinical site is 
requested by a regulatory authority , the investigator must inform Novartis immediately  that this 
request has been made.
13.3 Publication of study  protocol and results
The protocol will be registered in a publicly  accessible database such as clinicaltrials.gov and 
as required in EudraCT. In addition, after study  completion (defined as last patient last visit) 
and finalization of the study repor t the results of this trial will be submitted for publication and 
posted in a publicly  accessible database of clinical trial results, such as the Novartis clinical trial 
results website and all required Health Authority  websites (e.g. Clinicaltrials.gov, EudraCT 
etc.).

Novartis Confidential Page 96
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
For details on the Novartis publication policy  including authorship criteria, please refer to the 
Novartis publication policy training materials that were provided to you at the trial investigator 
meetings.
13.4 Qualit y Control and Quality  Assuran ce
Novartis maintains a robust Quality  Management System (QMS) that includes all activities 
involved in quality  assurance and qualit y control, to ensure compliance with written Standard 
Operating Procedures as well as applicable global/local GCP regulation s and I CH Guidelines.
Audits of investigator sites, vendors, and Novartis systems are performed by auditors, 
independent from those involved in conducting, monitoring or performing quality  control of the 
clinical trial. The clinical audit process uses a kn owledge/risk based approach.
Audits are conducted to assess GCP compliance with global and local regulatory requirements, 
protocols and internal SOPs, and are performed according to written Novartis processes .
14 Protocol adherence
This protocol defines the s tudy objectives, the study procedures and the data to be collected on 
study  participants. Additional assessments required to ensure safety  of subjects should be 
administered as deemed necessary  on a case by case basis. Under no circumstances including 
incidental collection is an investigator allowed to collect additional data or conduct any 
additional procedures for any purpose involving any investigational drugs under the protocol, 
other than the purpose of the study . If despite this interdiction prohibiti on, data, information, 
observation would be incidentally  collected, the investigator shall immediately  disclose it to 
Novartis and not use it for any purpose other than the study , except for the appropriate 
monitoring on study  participants.
Investigators ascertain they will apply due diligence to avoid protocol deviations. If an 
investigator feels a protocol deviation would improve the conduct of the study  this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by Novartis 
and approved by the IR B/IEC and health authorities, where required, it cannot be implemented.
14.1 Protocol A mendments
Any change or addition to the protocol can onl y be made in a written protocol amendment that 
must be approved by Novartis, health authorities where required, and the IRB/IEC prior to 
implementation.
Only  amendments that are required for subject safet y may be implemented immediately 
provided the health authorities are subsequently  notified by protocol amendment and the 
reviewing IRB/IEC is notifi ed.
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take any immediate action required for the safety  of any subject included in this 
study , even if this action represents a deviation from the protocol. In such cases, Novartis should 
be notified of this action and the IRB/IEC at the study  site should be informed according to 
local regulations.

Novartis Confidential Page 101
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
16 Appendices
16.1 Appendix 1: Clinically  notable laboratory  values and vital signs
The central laboratory  will flag laboratory  values falling outside of the normal ranges on 
thecentral laboratory reports. Investigators are responsible for reviewing these abnormal values 
for clinical significance, signing the laboratory  reports to indicate their review, and reporting 
values considered clinically  significant in the appropriate eCRF.
Any clinicall y significant abnormal laboratory  value should be evaluated and followed-up by 
the investigator until normal or a cause for the abnormality  is determined.
See Section 16.2 for specific liver event and laboratory  test trigger definitions and follow up 
requirements.
For ECGs, a notable QTc value is defined as a QTcF (Fridericia) interval of ≥ 450 msec for 
males or ≥ 460 msec for females –all such ECGs will be flagged by  the Central ECG reading 
and require assessment for clinical relevance and continuance of the patient by the Investigator.

Novartis Confidential Page 102
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
16.2 Appendix 2: Liver event and Laboratory  trigger Definitions and 
Follow -up Requirements
Table 16-1 Liver Event and Laboratory  Trigger Definitions
Definition/ threshold
LIVER LABORATORY TRIGGERS 3 x ULN < ALT / AST < 5 x ULN
· 1.5 x ULN < TBL < 2 x ULN
LIVER EVENTS ALT or AST > 5 × ULN
ALP > 2 × ULN (in the absence of known 
bone pathology)
TBL > 2 × ULN (in the absence of known 
Gilbert syndrome)
ALT or AST > 3 × ULN and PT/INR > 1.5
Potential Hy’s Law cases (defined as ALT or 
AST > 3 × ULN and TBL > 2 × ULN [mainly 
conjugated fraction] without notable increase 
in ALP to > 2 × ULN)
Any clinical event of jaundice (or equivalent 
term)
ALT or AST > 3 × ULN accompanied by 
(general) malaise, fatigue, abdominal pain, 
nausea, or vomiting, or rash with 
eosinophilia
Any adverse event potentially indicative of a 
liver toxicity*
*These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage-
related conditions; the non -infectious hepatitis; the benign, malignant and unspecified liver 
neoplasms TBL: total bilirubin; ULN: upper limit of normal
Table 16-2 Follo w Up Requirements for Liver Events and Laboratory  Triggers
Criteria Actions required Follow -up monitoring
Potential Hy’s Law caseaDiscontinue the study 
treatment immediately
Hospitalize, if clinically 
appropriate
Establish causality
Complete appropriate 
eCRF sALT, AST, TBL, Alb, PT/INR, 
ALP and G GT until resolutionc
(frequency at investigator 
discretion)
ALT or A ST
> 8 × ULN Discontinue the study 
treatment immediately
Hospitalize if clinically 
appropriate
Establish causalityALT, AST, TBL, Alb, PT/INR, 
ALP and G GT until resolutionc
(frequency at investigator 
discretion)

Novartis Confidential Page 103
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
Criteria Actions required Follow -up monitoring
Complete appropriate 
eCRF s
> 3 × ULN and PT/INR > 1.5 Discontinue the study 
treatment immediately
Hospitalize, if clinically 
appropriate
Establish causality
Complete appropriate 
eCRF sALT, AST, TBL, Alb, PT/INR, 
ALP and G GT until resolutionc
(frequency at investigator 
discretion)
> 5 to ≤ 8 × ULN Repeat LFT within 48 
hours
If elevation persists, 
conti nue follow -up 
monitoring
If elevation persists for 
more than 2 weeks, 
discontinue the study drug
Establish causality
Complete appropriate 
eCRF sALT, AST, TBL, Alb, PT/INR, 
ALP and G GT until resolutionc
(frequency at investigator 
discretion)
> 3 × ULN accompanied by 
symptomsbDiscontinue the study 
treatment immediately
Hospitalize if clinically 
appropriate
Establish causality
Complete appropriate 
eCRF sALT, AST, TBL, Alb, PT/INR, 
ALP and G GT until resolutionc
(frequency at investigator 
discretion)
> 3 to ≤ 5 × ULN (patient is 
asymptomatic)Repeat LFT within the next 
week
If elevation is confirmed, 
initiate close observation of 
the patientInvestigator discretion
Monitor LFT within 1 to 4 
weeks
ALP (isolated)
> 2 × ULN (in the absence of 
known bone pathology)Repeat LFT within 48 
hours
If elevation persists, 
establish causality
Complete appropriate 
eCRF sInvestigator discretion
Monitor LFT within 1 to 4 
weeks or at next visit
TBL (isolated)
> 2 × ULN (in the absence of 
known Gilbert syndrome)Repeat LFT within 48 
hours
Fractionation into direct 
and indirect bilirubin is 
requiredALT, AST, TBL, Alb, PT/INR, 
ALP and G GT until resolutionc
(frequency at investigator 
discretion)

Novartis Confidential Page 104
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
Criteria Actions required Follow -up monitoring
Complete appropriate 
eCRF sTest for hemoly sis (e.g.
reticulocytes, haptoglobin, 
unconjugated [indirect] 
bilirubin)
> 1.5 to ≤ 2 × ULN (patient is 
asymptomatic)Repeat LFT within the next 
week
If elevation is confirmed, 
initiate close observation of 
the patientInvestigator discretion
Monitor LFT within 1 to 4 
weeks or at next visit
Jaundice Discontinue the study 
treatment immediately
Hospitalize the patient
Establish causality
Complete appropriate 
eCRF sALT, AST, TBL, Alb, PT/INR, 
ALP and G GT until resolutionc
(frequency at investigator 
discretion)
Any AE potentially indicative of 
a liver toxicity*Consider study treatment 
interruption or 
discontinuation
Hospitalization if clinically 
appropriate
Establish causality
Complete appropriate 
eCRF sInvestigator discretion
aElevated ALT/AST > 3 × ULN and TBL > 2 × ULN but without notable increase in ALP to > 2 × ULN 
b(General) malaise, fatigue, abdominal pain, nausea, or vomiting, or rash with eosinophilia 
cResolution is defined as an outcome of one of the following: (1) retu rn to baseline values, (2) stable 
values at 3subsequent monitoring visits at least 2 weeks apart, (3) remain at elevated level after a 
maximum of 6 months, (4) liver transplantation, and (5) death.

Novartis Confidential Page 105
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
16.3 Appendix 3 Spirometry  guidance
Equipment
Spirometers must meet the specifications and performance criteria recommended in the 
American Thoracic Society  (ATS) /European Respiratory  Societ y (ERS) Standardization of 
Spirometry1. Spirometers must have the capacity  to print FVC tracings. All spirometry  values 
should be reported at body  temperature, pressure, saturated with water vapor (BTPS )by the 
method established by  the manufacturer.
Calibration
The spirometer should be calibrated every  morning before any spirometric measurements for 
the study  are performed. Calib ration reports should be printed and stored as source data at the 
site.
Preparing the test subject
On study  days when spirometry  will be performed, patients should refrain from the following:
Coffee, tea, chocolate, cola and other caffeine -containing beverages and foods and ice-
cold beverages for 4 hours prior to spirometry
Alcohol for 4 hours prior to spirometry
Strenuous activity  for 12 hours prior to spirometry
Smoking within at least 1 hour of testing
Exposure to environmental smoke, dust or areas with strong odors
Every  effort should be made to assure consistent testing conditions throughout the study . A 
seated position with nose clips is recommended to reduce risks related to dizziness or sy ncope. 
When possible, spirometry  should be conducted by the same technician using the same 
spirometer. To minimize the effects of diurnal variation on lung function, spirometry  visits 
should start at approximately  the same time of day at each visit.
Performing Spirometry
The subject’s age, height and gender will be entered into the spirometer. I t is important that the 
height is measured accurately  at the study  site. Spirometry , an effort -dependent test, requires 
careful instruction and cooperation of the subject. The technician should ensure a good seal 
around th e mouthpiece, and confirm that the subject’s posture is correct. The subject should be 
instructed to perform a maximal inspiration, followed by maximum forced expiration until no 
more air can be exhaled or for at least 6 seconds. Expiration must be rapid with exertion of 
maximal effort. The results of spirometry  should meet the ATS/ERS criteria for acceptability 
(one retest may  be performed for patients that don’t meet the acceptabilit y criteria).
Number of trials
A minimum of 3 acceptable forced vital capacity (FVC) maneuvers should be performed. If a 
subject is unable to perform a single acceptable maneuver after 8 attempts, testing should be 
discontinued.
Acceptability
An acceptable maneuver has the following characteristics:

Novartis Confidential Page 106
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
No hesitation or false start;
A rapid start;
No cough, especially  during the first second of the maneuver;
No glottic closure or obstruction by tongue or dentures
No earl y termination of exhalation (minimum exhalation time of 6 seconds is 
recommended, or no volume change for at least 1 second) or the subject cannot continue 
to exhale further
Repeatibility
The 2 largest FVC and FEV 1values from 3 acceptable maneuvers should not vary by more than 
0.150 L .
Recording of data
The highest FEV 1and FVC from any of the acceptable curves are re corded. (The highest FEV 1
and FVC may  not necessarily  result from the same acceptable curve).
Predicted normal
This study  will utilize the spirometric predication equation standards for the European 
Community  for Coal and Steel 2or Nhanes3 or Japanese Respiratory  Society4. Further details 
will be provided in a specification document for the central spirometry  assessments.
Reversibility
All reversibility  evaluations should follow the recommendations of the ATS/ERS Task force: 
Standardization of L ung Functio n Testing1.
Administer 400µg of salbutamol/albuterol following the completion of the pre-bronchodilator 
assessment. Post -bronchodilator spirometry  assessment is then performed 30 -60 minutes after 
administration of the salbumatol/albuterol.
Reversibility is calculated as:
100 x FEV 1(post -bronchodilator) – FEV 1(pre-bronchodilator)
FEV 1(pre-bronchodilator)
Following the reversibility  testing assessment for post-bronchodilator FEV 1, if lung function 
has been observed to have deteriorated (i.e. there is a decrease in post bronchodilator FEV 1
compared to pre-bronchodilator FEV 1as opposed to an increase ) after administration of 
salbutamol/albuterol, then the patient should repeat the visit, allowing at least 24 hours between 
visits (one retest may be performed in patients that demonstrate a deterioration in lung function 
post-bronchodilation) .
Patients with COPD demonstrating a high reversibility  may require further clinical evaluation
by the investigator to rule out a diagnosis of asthma.
References
1 Miller MR et al, Standardization of L ung Function Testing. Eur Resp J 2005;26:153 -161.

Novartis Confidential Page 107
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
2 Quanjer PH at al. Lung volumes and forced ventilatory  flows, Report Working Party 
Standardization of Lung Function Tests, European Community  for Steel and Coal. Official 
Statement of the European Respiratory  societ y. Eur Resp J 1993;6: Suppl. 16, 5 -40.
3 Hankinson JL , Odencrantz JR, Fedan KB (1999) Spirometric reference values from a sample 
of the gene ral US population. Am J Respir Crit Care Med 159:179 –187.
4Kubota, Kobay ashi, Quanjer PH, et al. Reference 
values for spirometry , including vital 
capacity , in Japanese adults calculated with the LMS method and compared with previous 
values. Clinical Pulmo nary Functions Committee of the Japanese Respiratory  Societ y. 
Respiratory  Investigations 2014, 242 -250.
16.4 Appendix 4 CA SA-Q
The sample provided here is for illustrative purposes only (US English version) .

Novartis Confidential Page 108
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201

Novartis Confidential Page 109
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201

Novartis Confidential Page 110
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201

Novartis Confidential Page 111
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201

Novartis Confidential Page 112
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201

Novartis Confidential Page 114
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
16.6 Appendix 6 EXA CT questionnaire
(The sample provided here is for illustrative purposes only )
The EXACT Total score is computed across 14 questions and has a theoretical range of 0 to 
100, with higher values indicating a more severe condition. The Total score is used in the 
determination of exacerbation frequency , severit y and duration of exacerbation. Specifically , 
changes in the Total score are used to define onset and recovery  from an exacerbation event and 
the magnit ude of the event.
The EXACT provides information on 3 exacerbation -related outcomes: frequency  (counts), 
severit y (score) and duration (days). Time to first event may also be examined.
Study site and patient training
Study  personnel should be trained on the following procedures to introduce a patient to the 
EXACT:
Sit down with the patient at the beginning of the study  and show them an example of the 
EXACT diary  in the device on which it is to be administered.
Inform the patient that the EXACT is to be comp leted every  evening, just before going to 
bed.
Instruct patients to reflect on their day  and answer the questions based on how they  felt 
over the day .
Instruct a patient to respond in a way  that is representative of the entire day .
Remind patients that there are no right or wrong answers.
Highlight for patients that the EXACT has 14 items.
All 14 items are to be answered daily  for the study period, as specified in the protocol.
Point out that answers cannot be skipped.
If a patient is unsure how to answer an item, instruct the patient to select the answer that 
best describes how they  feel.
The EXACT total score is the sum of the raw score of the EXACT 14 items.
The following lists the raw score values associated with each response category  for the EXACT 
items.

Novartis Confidential Page 119
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
16.8 Appendix 8 PGI
The sample provided here is for illustrative purposes only .
The PGI -S consists of PGI -S -general question and PGI -S -specific question:
PGI-S -general question :
Overall, how would you rate the severit y of your respiratory  symptoms in the last 7 days? 
(Please check one onl y)
0 Not at all
1 Slightly
2 Moderatel y
3 Severel y
4 Extremely
PGI-S -specific question :
Overall, how would you rate the severit y of your cough and mucus in the last 7 days? (Please 
check one only )
0 No cough and mucus
1 Very  Mild
2 Mild
3 Moderate
4 Severe
5 Very  Severe

Novartis Confidential Page 122
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201

Novartis Confidential Page 123
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
16.11 Appendix 11 e -Diary  (for rescue medication)
The following information will be captured twice daily before taking study  medication. In 
addition, patient will register an y stud y medication interruptions.
In the MORNING (pre -medication) In the EVENING (pre -medication)
Number of puffs of rescue medication during the 
past 12 hoursNumber of puffs of rescue medication during the 
past 12 hours
16.12 Appendix 12: SGRQ
The sample provided here is for illustrative purposes only .

Novartis Confidential Page 124
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201

Novartis Confidential Page 125
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201

Novartis Confidential Page 126
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201

Novartis Confidential Page 127
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201

Novartis Confidential Page 128
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201

Novartis Confidential Page 129
Amended Protocol Version 03 (Clean ) Protocol No. CQBW 251B2201
